{
  "$schema": "folio-library-document/v1",
  "id": "10665-340255",
  "title": "WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease",
  "variant": "pdf",
  "pages": 68,
  "tocSource": "outline",
  "tocMethod": null,
  "toc": [
    {
      "level": 1,
      "title": "Contents",
      "number": null,
      "page": 5,
      "pageLabel": "iii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-000-contents"
    },
    {
      "level": 2,
      "title": "Acknowledgements",
      "number": null,
      "page": 7,
      "pageLabel": "v",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-001-acknowledgements"
    },
    {
      "level": 2,
      "title": "Abbreviations and acronyms",
      "number": null,
      "page": 10,
      "pageLabel": "viii",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-002-abbreviations-and-acronyms"
    },
    {
      "level": 2,
      "title": "Definitions",
      "number": null,
      "page": 11,
      "pageLabel": "ix",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-003-definitions"
    },
    {
      "level": 2,
      "title": "Executive summary",
      "number": null,
      "page": 13,
      "pageLabel": "1",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-004-executive-summary"
    },
    {
      "level": 2,
      "title": "Introduction",
      "number": "1",
      "page": 17,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-005-1-introduction"
    },
    {
      "level": 3,
      "title": "Background",
      "number": "1.1",
      "page": 17,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-006-11-background"
    },
    {
      "level": 3,
      "title": "Definition and objectives of systematic screening for TB disease",
      "number": "1.2",
      "page": 17,
      "pageLabel": "5",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-007-12-definition-and-objectives-of-systematic-scree"
    },
    {
      "level": 3,
      "title": "Scope of the 2021 update",
      "number": "1.3",
      "page": 18,
      "pageLabel": "6",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-008-13-scope-of-the-2021-update"
    },
    {
      "level": 3,
      "title": "Rationale for the guideline update",
      "number": "1.4",
      "page": 20,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-009-14-rationale-for-the-guideline-update"
    },
    {
      "level": 3,
      "title": "Objectives of guideline update",
      "number": "1.5",
      "page": 20,
      "pageLabel": "8",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-010-15-objectives-of-guideline-update"
    },
    {
      "level": 3,
      "title": "Target audience",
      "number": "1.6",
      "page": 21,
      "pageLabel": "9",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-011-16-target-audience"
    },
    {
      "level": 2,
      "title": "Recommendations for systematic screening for TB disease in targeted populations",
      "number": "2",
      "page": 23,
      "pageLabel": "11",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-012-2-recommendations-for-systematic-screening-for-t"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease in the general population",
      "number": "2.1",
      "page": 25,
      "pageLabel": "13",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-013-21-systematic-screening-for-tb-disease-in-the-ge"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease among people with structural risk factors for TB",
      "number": "2.2",
      "page": 27,
      "pageLabel": "15",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-014-22-systematic-screening-for-tb-disease-among-peo"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease among people living with HIV",
      "number": "2.3",
      "page": 28,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-015-23-systematic-screening-for-tb-disease-among-peo"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease among household and other close contacts of individuals with TB disease",
      "number": "2.4",
      "page": 28,
      "pageLabel": "16",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-016-24-systematic-screening-for-tb-disease-among-hou"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease in prisons and other penitentiary institutions",
      "number": "2.5",
      "page": 30,
      "pageLabel": "18",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-017-25-systematic-screening-for-tb-disease-in-prison"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease among miners and others exposed to silica dust",
      "number": "2.6",
      "page": 31,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-018-26-systematic-screening-for-tb-disease-among-min"
    },
    {
      "level": 3,
      "title": "Systematic screening for TB disease among people attending health care services who have clinical risk factors for TB",
      "number": "2.7",
      "page": 31,
      "pageLabel": "19",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-019-27-systematic-screening-for-tb-disease-among-peo"
    },
    {
      "level": 2,
      "title": "Recommendations for tools for systematic screening for TB disease",
      "number": "3",
      "page": 35,
      "pageLabel": "23",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-020-3-recommendations-for-tools-for-systematic-scree"
    },
    {
      "level": 3,
      "title": "Tools for screening for TB disease among the general population and high-risk groups",
      "number": "3.1",
      "page": 35,
      "pageLabel": "23",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-021-31-tools-for-screening-for-tb-disease-among-the"
    },
    {
      "level": 3,
      "title": "Use of computer-aided detection software for automated reading of digital chest radiographs",
      "number": "3.2",
      "page": 37,
      "pageLabel": "25",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-022-32-use-of-computer-aided-detection-software-for"
    },
    {
      "level": 3,
      "title": "Tools for screening for TB disease among people living with HIV",
      "number": "3.3",
      "page": 40,
      "pageLabel": "28",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-023-33-tools-for-screening-for-tb-disease-among-peop"
    },
    {
      "level": 3,
      "title": "Tools for systematic screening for TB disease among children and adolescents",
      "number": "3.4",
      "page": 47,
      "pageLabel": "35",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-024-34-tools-for-systematic-screening-for-tb-disease"
    },
    {
      "level": 2,
      "title": "Monitoring and evaluation",
      "number": "4",
      "page": 49,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-025-4-monitoring-and-evaluation"
    },
    {
      "level": 3,
      "title": "Indicators",
      "number": "4.1",
      "page": 49,
      "pageLabel": "37",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-026-41-indicators"
    },
    {
      "level": 3,
      "title": "Routines for recording and reporting",
      "number": "4.2",
      "page": 50,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-027-42-routines-for-recording-and-reporting"
    },
    {
      "level": 3,
      "title": "Programmatic evaluations",
      "number": "4.3",
      "page": 50,
      "pageLabel": "38",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-028-43-programmatic-evaluations"
    },
    {
      "level": 3,
      "title": "Initial calibration for computer-aided detection technologies",
      "number": "4.4",
      "page": 51,
      "pageLabel": "39",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-029-44-initial-calibration-for-computer-aided-detect"
    },
    {
      "level": 2,
      "title": "Research gaps",
      "number": "5",
      "page": 53,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-030-5-research-gaps"
    },
    {
      "level": 3,
      "title": "Screening for TB in targeted populations",
      "number": "5.1",
      "page": 53,
      "pageLabel": "41",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-031-51-screening-for-tb-in-targeted-populations"
    },
    {
      "level": 3,
      "title": "Tools for screening for TB",
      "number": "5.2",
      "page": 54,
      "pageLabel": "42",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-032-52-tools-for-screening-for-tb"
    },
    {
      "level": 3,
      "title": "Operational research",
      "number": "5.3",
      "page": 55,
      "pageLabel": "43",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-033-53-operational-research"
    },
    {
      "level": 2,
      "title": "References",
      "number": "6",
      "page": 57,
      "pageLabel": "45",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-034-6-references"
    },
    {
      "level": 2,
      "title": "Supplementary Table",
      "number": null,
      "page": 63,
      "pageLabel": "51",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-036-supplementary-table"
    },
    {
      "level": 3,
      "title": "Summary of changes to existing recommendations",
      "number": null,
      "page": 63,
      "pageLabel": "51",
      "confidence": null,
      "evidence": null,
      "source": "outline",
      "section": "sec-035-summary-of-changes-to-existing-recommendations"
    }
  ],
  "sections": [
    {
      "id": "sec-front-matter",
      "number": null,
      "title": "Front matter",
      "level": 1,
      "pageStart": 1,
      "pageEnd": 5,
      "labelStart": "a",
      "labelEnd": "iii",
      "words": 532,
      "summary": {
        "text": "The cover, title and copyright pages of the 2021 WHO consolidated guidelines on tuberculosis, Module 2: systematic screening for TB disease, with ISBNs, Creative Commons licence terms, suggested citation and disclaimers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening systematic",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "creative commons",
          "heading": false
        },
        {
          "term": "consolidated guidelines",
          "heading": false
        },
        {
          "term": "suggested citation",
          "heading": false
        },
        {
          "term": "licence",
          "heading": false
        },
        {
          "term": "health organization",
          "heading": false
        },
        {
          "term": "world health",
          "heading": false
        }
      ],
      "extract": "Module 2: Screening Systematic screening for tuberculosis disease WHO consolidated guidelines on tuberculosis Systematic screening for tuberculosis disease Module 2: Screening WHO consolidated guidelines on tuberculosis WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease ISBN 978–92–4-002267–6 (electronic version) ISBN 978–92–4-002268–3 (print version) ©",
      "extractCut": true,
      "blocks": [
        "library/10665-340255/blocks/prose-sec-front-matter"
      ]
    },
    {
      "id": "sec-000-contents",
      "number": null,
      "title": "Contents",
      "level": 1,
      "pageStart": 5,
      "pageEnd": 7,
      "labelStart": "iii",
      "labelEnd": "v",
      "words": 324,
      "summary": {
        "text": "The table of contents, listing chapters on recommendations for target populations, screening tools, monitoring and evaluation and research gaps, plus links to three web annexes on methods and GRADE evidence tables.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "disease among",
          "heading": false
        },
        {
          "term": "computer-aided detection",
          "heading": false
        },
        {
          "term": "among people",
          "heading": false
        },
        {
          "term": "web annex",
          "heading": false
        },
        {
          "term": "guideline update",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "targeted populations",
          "heading": false
        }
      ],
      "extract": "Acknowledgements\b v Abbreviations and acronyms\b viii Definitions\b ix Executive summary\b 1 1. Introduction\b 5 1.1 Background\b 5 1.2 Definition and objectives of systematic screening for TB disease\b 5 1.3 Scope of the 2021 update\b 6 1.4 Rationale for the guideline update\b 8 1.5 Objectives of the guideline update\b 8 1.6 Target audience\b 9 2. Recommendations for systematic screening for TB disease in targeted",
      "extractCut": true
    },
    {
      "id": "sec-001-acknowledgements",
      "number": null,
      "title": "Acknowledgements",
      "level": 2,
      "pageStart": 7,
      "pageEnd": 10,
      "labelStart": "v",
      "labelEnd": "viii",
      "words": 1089,
      "summary": {
        "text": "Credits the WHO Global Tuberculosis Programme staff who coordinated and wrote the TB screening guidelines and names the funders. It lists members of the Guideline Development Group, the external review group, evidence reviewers and others who contributed.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "united kingdom",
          "heading": false
        },
        {
          "term": "pico question",
          "heading": false
        },
        {
          "term": "tropical medicine",
          "heading": false
        },
        {
          "term": "liverpool school",
          "heading": false
        },
        {
          "term": "karolinska institute",
          "heading": false
        },
        {
          "term": "london school",
          "heading": false
        },
        {
          "term": "tamara kredo",
          "heading": false
        },
        {
          "term": "annabel baddeley",
          "heading": false
        }
      ],
      "extract": "Acknowledgements The production of the WHO consolidated guidelines on tuberculosis. Module 2: screening was coordinated and written by Cecily Miller, with support from Annabel Baddeley, Dennis Falzon and Matteo Zignol, under the overall direction of Tereza Kasaeva, Director of the World Health Organization (WHO) Global Tuberculosis Programme. The WHO Global Tuberculosis Programme gratefully acknowledges the",
      "extractCut": true
    },
    {
      "id": "sec-002-abbreviations-and-acronyms",
      "number": null,
      "title": "Abbreviations and acronyms",
      "level": 2,
      "pageStart": 10,
      "pageEnd": 11,
      "labelStart": "viii",
      "labelEnd": "ix",
      "words": 91,
      "summary": {
        "text": "Lists the abbreviations and acronyms used in the TB screening guidelines, such as CAD, CXR, mWRD, NNS and W4SS.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chest",
          "heading": false
        },
        {
          "term": "who-recommended",
          "heading": false
        },
        {
          "term": "w4ss",
          "heading": false
        },
        {
          "term": "nns",
          "heading": false
        }
      ],
      "extract": "ART antiretroviral treatment CAD computer-aided detection of TB-related abnormalities on chest radiography CI confidence interval CRP C-reactive protein CXR chest radiograph (chest X-ray) ERG External Review Group GDG Guideline Development Group GRADE Grading of Recommendations Assessment, Development and Evaluation IPD individual patient data LF-LAM lateral flow urine lipoarabinomannan assay mWRD molecular",
      "extractCut": true
    },
    {
      "id": "sec-003-definitions",
      "number": null,
      "title": "Definitions",
      "level": 2,
      "pageStart": 11,
      "pageEnd": 13,
      "labelStart": "ix",
      "labelEnd": "1",
      "words": 581,
      "summary": {
        "text": "Defines the key terms used in the TB screening guidelines, including active, enhanced and passive case-finding, computer-aided detection, number needed to screen and repeat screening. It also explains initial screening, triage and the meaning of TB disease as distinct from TB infection.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "tuberculosis disease",
          "heading": false
        },
        {
          "term": "case-finding",
          "heading": false
        },
        {
          "term": "active tuberculosis",
          "heading": false
        },
        {
          "term": "undergo further",
          "heading": false
        },
        {
          "term": "definitions",
          "heading": true
        },
        {
          "term": "procedure",
          "heading": false
        }
      ],
      "extract": "Definitions The definitions below apply to terms as used in these guidelines, and they may have different meanings elsewhere. Active (tuberculosis) case-finding (ACF): Provider-initiated screening and testing in communities by mobile teams, often using mobile X-ray and rapid molecular tests. The term is sometimes used synonymously with “systematic screening”. Computer-aided detection (CAD): The use of specialized",
      "extractCut": true
    },
    {
      "id": "sec-004-executive-summary",
      "number": null,
      "title": "Executive summary",
      "level": 2,
      "pageStart": 13,
      "pageEnd": 17,
      "labelStart": "1",
      "labelEnd": "5",
      "words": 1963,
      "summary": {
        "text": "Summarizes why WHO updated its 2013 guidance on systematic TB screening, citing the 2.9 million people with TB who went undiagnosed or unreported in 2019 and global targets for diagnosis. It explains that a Guideline Development Group reviewed new evidence in 2020, including on computer-aided detection of chest X-rays, C-reactive protein and rapid molecular tests. The summary presents the recommendations on which populations to screen and which tools to use, ending with a box on the main changes from the earlier guidance.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "symptom screening",
          "heading": false
        },
        {
          "term": "who-recommended four-symptom",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "symptom screen",
          "heading": false
        },
        {
          "term": "c-reactive protein",
          "heading": false
        },
        {
          "term": "updated recommendation",
          "heading": false
        },
        {
          "term": "screening systematic",
          "heading": false
        }
      ],
      "extract": "Executive summary Tuberculosis (TB) is a leading cause of death from a single infectious agent, despite being largely curable and preventable. In 2019 an estimated 2.9 million of the 10 million people who fell ill with TB were not diagnosed or reported to the World Health Organization (WHO). The Political Declaration adopted by the United Nations General Assembly in September 2018 at the High-Level Meeting on the",
      "extractCut": true
    },
    {
      "id": "sec-005-1-introduction",
      "number": "1",
      "title": "Introduction",
      "level": 2,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 0,
      "summary": null,
      "keywords": [],
      "extract": null,
      "extractCut": false
    },
    {
      "id": "sec-006-11-background",
      "number": "1.1",
      "title": "Background",
      "level": 3,
      "pageStart": 17,
      "pageEnd": 17,
      "labelStart": "5",
      "labelEnd": "5",
      "words": 279,
      "summary": {
        "text": "Gives the background to the update, noting the gap in TB diagnosis, the End TB Strategy and UN targets, and the new evidence on screening since WHO's 2013 guidelines.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "million people",
          "heading": false
        },
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "reduction",
          "heading": false
        },
        {
          "term": "evaluating",
          "heading": false
        },
        {
          "term": "disease",
          "heading": false
        },
        {
          "term": "end",
          "heading": false
        },
        {
          "term": "strategy",
          "heading": false
        }
      ],
      "extract": "Tuberculosis (TB) is a leading cause of death from a single infectious agent, despite being largely curable and preventable. In 2019, an estimated 2.9 million of the 10 million people who fell ill with TB were not diagnosed or reported to the World Health Organization (WHO) (1). WHO’s End TB Strategy envisions a 90% reduction in TB incidence and a 95% reduction in TB deaths by 2035 (2, 3), and the Declaration",
      "extractCut": true
    },
    {
      "id": "sec-007-12-definition-and-objectives-of-systematic-scree",
      "number": "1.2",
      "title": "Definition and objectives of systematic screening for TB disease",
      "level": 3,
      "pageStart": 17,
      "pageEnd": 18,
      "labelStart": "5",
      "labelEnd": "6",
      "words": 580,
      "summary": {
        "text": "Defines systematic screening for TB disease as provider-initiated identification of people at risk in a target group using rapid tests, followed by diagnostic confirmation. It sets out the two aims of screening: early detection and treatment for individuals, and reduced transmission and incidence in the population.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systematic screening",
          "heading": true
        },
        {
          "term": "disease",
          "heading": true
        },
        {
          "term": "averting future",
          "heading": false
        },
        {
          "term": "people seeking",
          "heading": false
        },
        {
          "term": "screening interventions",
          "heading": false
        },
        {
          "term": "seeking care",
          "heading": false
        },
        {
          "term": "future incident",
          "heading": false
        },
        {
          "term": "health care",
          "heading": false
        }
      ],
      "extract": "for TB disease For the purpose of this guideline, systematic screening for TB disease is defined as the systematic identification of people at risk for TB disease, in a predetermined target group, by assessing symptoms and using tests, examinations or other procedures that can be applied rapidly. The screening tests, examinations and other procedures should efficiently distinguish people with a high probability of",
      "extractCut": true
    },
    {
      "id": "sec-008-13-scope-of-the-2021-update",
      "number": "1.3",
      "title": "Scope of the 2021 update",
      "level": 3,
      "pageStart": 18,
      "pageEnd": 20,
      "labelStart": "6",
      "labelEnd": "8",
      "words": 682,
      "summary": {
        "text": "Presents the conceptual framework for the 2021 update, linking screening inputs and activities to individual and population outcomes such as earlier diagnosis, better treatment results and reduced transmission. It then lists the PICO and background questions used to gather evidence, covering effectiveness, screening tool accuracy, numbers needed to screen, risk factors, costs and community attitudes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "passive case-finding",
          "heading": false
        },
        {
          "term": "case-finding alone",
          "heading": false
        },
        {
          "term": "screening interventions",
          "heading": false
        },
        {
          "term": "screening tools",
          "heading": false
        },
        {
          "term": "through passive",
          "heading": false
        },
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "disease compared",
          "heading": false
        },
        {
          "term": "pico questions",
          "heading": false
        }
      ],
      "extract": "Fig. 1 summarizes the potential contribution of TB screening to standard TB care practices based on the above frameworks for TB screening and shows the conceptual framework that guided the 2021 update to the TB screening guidelines. Fig. 1. Conceptual framework for the 2021 WHO update to guidelines for systematic screening for TB. Numbers in parentheses refer to the PICO (population, intervention, comparator and",
      "extractCut": true
    },
    {
      "id": "sec-009-14-rationale-for-the-guideline-update",
      "number": "1.4",
      "title": "Rationale for the guideline update",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 20,
      "labelStart": "8",
      "labelEnd": "8",
      "words": 93,
      "summary": {
        "text": "Explains that the update was prompted by many new studies on screening impact and by prevalence surveys showing a larger TB burden than previously thought.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "prevalence surveys",
          "heading": false
        },
        {
          "term": "numerous",
          "heading": false
        },
        {
          "term": "shed",
          "heading": false
        }
      ],
      "extract": "Since the publication of the first WHO guidelines on systematic screening for TB in 2013 (5), there have been numerous studies, including reviews, randomized controlled trials, observational studies, modelling and cost–effectiveness research, evaluating the real or potential impacts of screening interventions on both individual-level and community-level outcomes related to TB. There have also been numerous",
      "extractCut": true
    },
    {
      "id": "sec-010-15-objectives-of-guideline-update",
      "number": "1.5",
      "title": "Objectives of guideline update",
      "level": 3,
      "pageStart": 20,
      "pageEnd": 21,
      "labelStart": "8",
      "labelEnd": "9",
      "words": 149,
      "summary": {
        "text": "States the objectives of the update: to help countries implement effective screening with current evidence on impact, yield and tool performance, and to find more people with TB earlier.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening interventions",
          "heading": false
        },
        {
          "term": "update",
          "heading": true
        },
        {
          "term": "finding",
          "heading": false
        },
        {
          "term": "expected",
          "heading": false
        }
      ],
      "extract": "The specific objectives of the guideline update are: 1. to support Member States in implementing effective TB screening interventions by providing updated information about the expected impact of TB screening on patient-important outcomes and the epidemiology of TB, the expected yield of screening interventions and the expected performance of different screening tools and algorithms; 2. to contribute to finding more",
      "extractCut": true
    },
    {
      "id": "sec-011-16-target-audience",
      "number": "1.6",
      "title": "Target audience",
      "level": 3,
      "pageStart": 21,
      "pageEnd": 23,
      "labelStart": "9",
      "labelEnd": "11",
      "words": 149,
      "summary": {
        "text": "Identifies the intended readers of the guideline, such as national TB and HIV programme staff, policymakers and clinicians, and points to an accompanying operational handbook for adapting the recommendations locally.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "public health",
          "heading": false
        },
        {
          "term": "operational handbook",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "subnational",
          "heading": false
        },
        {
          "term": "working",
          "heading": false
        }
      ],
      "extract": "This guideline is intended for personnel working in national TB programmes, national HIV/AIDS programmes or their equivalents, and other relevant national health programmes in ministries of health; other relevant ministries working in public health and screening; and for other health policymakers, clinicians and public health practitioners working on TB, HIV and infectious diseases in the public and private sectors.",
      "extractCut": true
    },
    {
      "id": "sec-012-2-recommendations-for-systematic-screening-for-t",
      "number": "2",
      "title": "Recommendations for systematic screening for TB disease in targeted populations",
      "level": 2,
      "pageStart": 23,
      "pageEnd": 25,
      "labelStart": "11",
      "labelEnd": "13",
      "words": 1680,
      "summary": {
        "text": "Introduces the population-specific recommendations, explaining that screening may cover whole communities or be targeted at higher-risk groups and how strong and conditional recommendations are distinguished. It sets out the recommendation on screening the general population in high-prevalence settings. The evidence reviewed includes trials and studies in which community-wide screening reduced TB prevalence or infection among children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "systematic screening",
          "heading": true
        },
        {
          "term": "offered screening",
          "heading": false
        },
        {
          "term": "screening population",
          "heading": false
        },
        {
          "term": "through screening",
          "heading": false
        },
        {
          "term": "disease",
          "heading": true
        },
        {
          "term": "desirable effects",
          "heading": false
        },
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "screening test",
          "heading": false
        }
      ],
      "extract": "systematic screening for TB disease in targeted populations In this guideline, recommendations about systematic screening for TB disease are made for distinct populations for whom it is judged that the benefits and desirable effects of screening outweigh the potential harms. Systematic screening for TB disease can be done for an entire population (community-wide screening) or it can be targeted at selected risk",
      "extractCut": true
    },
    {
      "id": "sec-013-21-systematic-screening-for-tb-disease-in-the-ge",
      "number": "2.1",
      "title": "Systematic screening for TB disease in the general population",
      "level": 3,
      "pageStart": 25,
      "pageEnd": 27,
      "labelStart": "13",
      "labelEnd": "15",
      "words": 676,
      "summary": {
        "text": "Explains why the prevalence threshold for general population screening was lowered from 1% to 0.5% undetected TB, and discusses implementation factors such as prevalence, coverage and the sensitivity of screening algorithms. It also covers possible harms and concerns of people being screened, such as stigma and confidentiality.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "population-wide screening",
          "heading": false
        },
        {
          "term": "screening algorithm",
          "heading": false
        },
        {
          "term": "symptom-based screening",
          "heading": false
        },
        {
          "term": "general population",
          "heading": true
        },
        {
          "term": "accurate screening",
          "heading": false
        },
        {
          "term": "symptom screening",
          "heading": false
        },
        {
          "term": "sensitive screening",
          "heading": false
        }
      ],
      "extract": "population was recommended in defined populations with extremely high levels of undetected TB, defined as a 1% prevalence or higher. Based on the updated evidence reviewed, the GDG concluded that the threshold of 1% recommended in the 2013 guidelines could be lowered, but considered that screening under programmatic conditions would not perform as well as was observed in the trial in Viet Nam and, therefore,",
      "extractCut": true
    },
    {
      "id": "sec-014-22-systematic-screening-for-tb-disease-among-peo",
      "number": "2.2",
      "title": "Systematic screening for TB disease among people with structural risk factors for TB",
      "level": 3,
      "pageStart": 27,
      "pageEnd": 28,
      "labelStart": "15",
      "labelEnd": "16",
      "words": 462,
      "summary": {
        "text": "Gives the conditional recommendation to screen groups with structural risk factors, such as urban poor, homeless, remote, indigenous, migrant and displaced populations, and explains these risk factors. It notes that no new evidence was found since 2013 and offers implementation advice, including combining TB screening with other health activities.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "structural risk",
          "heading": true
        },
        {
          "term": "risk factors",
          "heading": true
        },
        {
          "term": "systematic screening",
          "heading": true
        },
        {
          "term": "displaced populations",
          "heading": false
        },
        {
          "term": "poor access",
          "heading": false
        },
        {
          "term": "risk groups",
          "heading": false
        },
        {
          "term": "populations affected",
          "heading": false
        },
        {
          "term": "conducted among",
          "heading": false
        }
      ],
      "extract": "people with structural risk factors for TB 2. Systematic screening for TB disease may be conducted among subpopulations with structural risk factors for TB. These include urban poor communities, homeless communities, communities in remote or isolated areas, indigenous populations, migrants, refugees, internally displaced persons and other vulnerable or marginalized groups with limited access to health care (existing",
      "extractCut": true
    },
    {
      "id": "sec-015-23-systematic-screening-for-tb-disease-among-peo",
      "number": "2.3",
      "title": "Systematic screening for TB disease among people living with HIV",
      "level": 3,
      "pageStart": 28,
      "pageEnd": 28,
      "labelStart": "16",
      "labelEnd": "16",
      "words": 291,
      "summary": {
        "text": "Sets out the strong recommendation that people living with HIV be screened for TB at every health facility visit, citing their much higher TB risk, and describes follow-up diagnostic testing and preventive treatment.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "people living",
          "heading": true
        },
        {
          "term": "hiv",
          "heading": true
        },
        {
          "term": "disease",
          "heading": true
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "screening test",
          "heading": false
        },
        {
          "term": "recommendation",
          "heading": false
        },
        {
          "term": "ensuring",
          "heading": false
        },
        {
          "term": "among",
          "heading": true
        }
      ],
      "extract": "people living with HIV 3. People living with HIV should be systematically screened for TB disease at each visit to a health facility (existing recommendation: strong recommendation, very low certainty of evidence). 2.3.1 Summary of evidence and rationale People living with HIV are approximately 19 times more likely to develop TB disease than those without HIV; in 2019, an estimated 44% of people living with HIV who",
      "extractCut": true
    },
    {
      "id": "sec-016-24-systematic-screening-for-tb-disease-among-hou",
      "number": "2.4",
      "title": "Systematic screening for TB disease among household and other close contacts of individuals with TB disease",
      "level": 3,
      "pageStart": 28,
      "pageEnd": 30,
      "labelStart": "16",
      "labelEnd": "18",
      "words": 866,
      "summary": {
        "text": "Gives the updated strong recommendation to screen household and close contacts of people with TB, citing a pooled disease prevalence of 3.6% and trials in Viet Nam, South Africa and Zambia showing benefits. It then covers implementation, including prioritizing contacts and offering HIV testing and preventive treatment where appropriate.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "household contacts",
          "heading": true
        },
        {
          "term": "close contacts",
          "heading": true
        },
        {
          "term": "among contacts",
          "heading": true
        },
        {
          "term": "screening household",
          "heading": true
        },
        {
          "term": "median nns",
          "heading": false
        },
        {
          "term": "weighted pooled",
          "heading": false
        },
        {
          "term": "disease",
          "heading": true
        },
        {
          "term": "pooled prevalence",
          "heading": false
        }
      ],
      "extract": "household and other close contacts of individuals with TB disease 4. Household contacts and other close contacts of individuals with TB disease should be systematically screened for TB disease (updated recommendation: strong recommendation, moderate certainty of evidence). 2.4.1 Summary of evidence and rationale Household and close contacts of individuals with TB disease are at high risk of TB infection and",
      "extractCut": true
    },
    {
      "id": "sec-017-25-systematic-screening-for-tb-disease-in-prison",
      "number": "2.5",
      "title": "Systematic screening for TB disease in prisons and other penitentiary institutions",
      "level": 3,
      "pageStart": 30,
      "pageEnd": 31,
      "labelStart": "18",
      "labelEnd": "19",
      "words": 604,
      "summary": {
        "text": "Presents the updated strong recommendation for TB screening in prisons, citing a much higher TB incidence among prisoners and studies showing earlier and increased case detection. Implementation advice covers screening at entry and periodically, infection control and access to diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "penitentiary institutions",
          "heading": true
        },
        {
          "term": "prisons",
          "heading": true
        },
        {
          "term": "systematic screening",
          "heading": true
        },
        {
          "term": "people residing",
          "heading": false
        },
        {
          "term": "correctional facility",
          "heading": false
        },
        {
          "term": "through screening",
          "heading": false
        },
        {
          "term": "gdg felt",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        }
      ],
      "extract": "and other penitentiary institutions 5. Systematic screening for TB disease should be conducted in prisons and penitentiary institutions (updated recommendation: strong recommendation, very low certainty of evidence). 2.5.1 Summary of evidence and rationale People in prisons and other penitentiary institutions are at an increased risk for TB compared with the general population, and they often have limited access to",
      "extractCut": true
    },
    {
      "id": "sec-018-26-systematic-screening-for-tb-disease-among-min",
      "number": "2.6",
      "title": "Systematic screening for TB disease among miners and others exposed to silica dust",
      "level": 3,
      "pageStart": 31,
      "pageEnd": 31,
      "labelStart": "19",
      "labelEnd": "19",
      "words": 306,
      "summary": {
        "text": "Sets out the strong recommendation to screen current and former workers exposed to silica dust, given the high TB risk linked to silicosis, and advises screening at least every 12 months, ideally combined with improvements to working conditions.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "silica dust",
          "heading": true
        },
        {
          "term": "miners",
          "heading": true
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "silicosis",
          "heading": false
        },
        {
          "term": "exposed",
          "heading": true
        },
        {
          "term": "workplaces",
          "heading": false
        },
        {
          "term": "disease",
          "heading": true
        },
        {
          "term": "among",
          "heading": true
        }
      ],
      "extract": "miners and others exposed to silica dust 6. Current and former workers in workplaces with silica exposure should be systematically screened for TB disease (existing recommendation: strong recommendation, low certainty of evidence). 2.6.1 Summary of evidence and rationale Exposure to silica dust and silicosis are among the strongest risk factors for TB, with a relative risk of 2.8–39 for silicosis, depending on the",
      "extractCut": true
    },
    {
      "id": "sec-019-27-systematic-screening-for-tb-disease-among-peo",
      "number": "2.7",
      "title": "Systematic screening for TB disease among people attending health care services who have clinical risk factors for TB",
      "level": 3,
      "pageStart": 31,
      "pageEnd": 35,
      "labelStart": "19",
      "labelEnd": "23",
      "words": 1998,
      "summary": {
        "text": "Gives conditional recommendations to screen people with clinical TB risk factors in health care settings where prevalence is at least 100 per 100,000, and people with untreated fibrotic lesions on chest X-ray. It reviews evidence on risk factors such as HIV, diabetes, malnutrition, smoking and alcohol use, summarized in a table. Implementation points include prioritizing groups according to local epidemiology, offering preventive treatment where appropriate and considering screening of health care workers.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "risk factors",
          "heading": true
        },
        {
          "term": "systematic screening",
          "heading": true
        },
        {
          "term": "clinical risk",
          "heading": true
        },
        {
          "term": "people attending",
          "heading": true
        },
        {
          "term": "among people",
          "heading": true
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "diabetes mellitus",
          "heading": false
        },
        {
          "term": "health care",
          "heading": true
        }
      ],
      "extract": "people attending health care services who have clinical risk factors for TB 7. In settings where the TB prevalence in the general population is 100/100 000 population or higher, systematic screening for TB disease may be conducted among people with a risk factor for TB who are either seeking health care or who are already in care (existing recommendation: conditional recommendation, very low certainty of evidence).",
      "extractCut": true
    },
    {
      "id": "sec-020-3-recommendations-for-tools-for-systematic-scree",
      "number": "3",
      "title": "Recommendations for tools for systematic screening for TB disease",
      "level": 2,
      "pageStart": 35,
      "pageEnd": 35,
      "labelStart": "23",
      "labelEnd": "23",
      "words": 243,
      "summary": {
        "text": "Introduces the recommendations on screening tools, explaining that tools separate people likely to have TB from those unlikely to have it and must be followed by diagnostic tests, and cites WHO target accuracy benchmarks.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening tools",
          "heading": true
        },
        {
          "term": "disease",
          "heading": true
        },
        {
          "term": "screening tests",
          "heading": false
        },
        {
          "term": "rule",
          "heading": false
        },
        {
          "term": "desirable",
          "heading": false
        },
        {
          "term": "probability",
          "heading": false
        },
        {
          "term": "systematic",
          "heading": true
        }
      ],
      "extract": "for systematic screening for TB disease TB screening tools are designed to distinguish people with a higher probability of having TB disease from those with a low probability and can be assumed to be free of TB disease. They are not intended to provide a definitive diagnosis. In general, they need to be able to be implemented easily and relay results rapidly in order to be informative in a screening context.",
      "extractCut": true
    },
    {
      "id": "sec-021-31-tools-for-screening-for-tb-disease-among-the",
      "number": "3.1",
      "title": "Tools for screening for TB disease among the general population and high-risk groups",
      "level": 3,
      "pageStart": 35,
      "pageEnd": 37,
      "labelStart": "23",
      "labelEnd": "25",
      "words": 1003,
      "summary": {
        "text": "Recommends that people aged 15 and over in groups eligible for screening may be screened with symptom questions, chest X-ray or rapid molecular tests, alone or combined. It summarizes systematic review evidence on the accuracy of each tool, with a table of sensitivity and specificity. The section closes by advising countries to fit these tools into national algorithms according to goals, resources and equity.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening tools",
          "heading": true
        },
        {
          "term": "ionizing radiation",
          "heading": false
        },
        {
          "term": "symptom screening",
          "heading": false
        },
        {
          "term": "high-risk groups",
          "heading": true
        },
        {
          "term": "chest radiography",
          "heading": false
        },
        {
          "term": "general population",
          "heading": true
        },
        {
          "term": "radiation dose",
          "heading": false
        },
        {
          "term": "screening conducted",
          "heading": false
        }
      ],
      "extract": "general population and high-risk groups 9. Among individuals aged 15 years and older in populations in which TB screening is recommended, systematic screening for TB disease may be conducted using a symptom screen, chest X-ray or molecular WHO-recommended rapid diagnostic tests, alone or in combination (new recommendation: conditional recommendation, very low certainty of evidence for test accuracy). 3.1.1 Summary",
      "extractCut": true
    },
    {
      "id": "sec-022-32-use-of-computer-aided-detection-software-for",
      "number": "3.2",
      "title": "Use of computer-aided detection software for automated reading of digital chest radiographs",
      "level": 3,
      "pageStart": 37,
      "pageEnd": 40,
      "labelStart": "25",
      "labelEnd": "28",
      "words": 1574,
      "summary": {
        "text": "Presents a new conditional recommendation that computer-aided detection software may replace human readers in interpreting digital chest X-rays for TB screening and triage in people aged 15 and over. It explains that chest radiography is limited by shortages of trained readers and variability between readers, and that many software packages now estimate the likelihood of TB. It ends with implementation needs such as digital radiography equipment, stable internet and maintenance, noting that costs depend on the setting.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "chest radiographs",
          "heading": true
        },
        {
          "term": "cad software",
          "heading": false
        },
        {
          "term": "digital chest",
          "heading": true
        },
        {
          "term": "cad technologies",
          "heading": false
        },
        {
          "term": "computer-aided detection",
          "heading": true
        },
        {
          "term": "human readers",
          "heading": false
        },
        {
          "term": "triage test",
          "heading": false
        },
        {
          "term": "cxrs",
          "heading": false
        }
      ],
      "extract": "automated reading of digital chest radiographs 10. Among individuals aged 15 years and older in populations in which TB screening is recommended, computer-aided detection software programmes may be used in place of human readers for interpreting digital chest X-rays for screening and triage for TB disease (new recommendation: conditional recommendation, low certainty of evidence). 3.2.1 Summary of the evidence and",
      "extractCut": true
    },
    {
      "id": "sec-023-33-tools-for-screening-for-tb-disease-among-peop",
      "number": "3.3",
      "title": "Tools for screening for TB disease among people living with HIV",
      "level": 3,
      "pageStart": 40,
      "pageEnd": 47,
      "labelStart": "28",
      "labelEnd": "35",
      "words": 3660,
      "summary": {
        "text": "Sets out recommendations on tools for TB screening among adults and adolescents living with HIV, keeping the four-symptom screen and adding C-reactive protein above 5 mg/L, chest X-ray and molecular rapid tests as options. It also strongly recommends systematic molecular testing of HIV inpatients in medical wards where TB prevalence exceeds 10%. The section summarises the evidence on the accuracy of these tools, as the start and end of this cut block show. It ends by encouraging countries to monitor screening yield among people with HIV by screening tool.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "people living",
          "heading": true
        },
        {
          "term": "screening among",
          "heading": true
        },
        {
          "term": "w4ss among",
          "heading": false
        },
        {
          "term": "w4ss alone",
          "heading": false
        },
        {
          "term": "screening tools",
          "heading": true
        },
        {
          "term": "w4ss followed",
          "heading": false
        },
        {
          "term": "mwrd alone",
          "heading": false
        },
        {
          "term": "inpatients living",
          "heading": false
        }
      ],
      "extract": "living with HIV 11. Among adults and adolescents living with HIV, systematic screening for TB disease should be conducted using the WHO-recommended four symptom screen and those who report any one of the symptoms of current cough, fever, weight loss or night sweats may have TB and should be evaluated for TB and other diseases (existing recommendation: strong recommendation, moderate certainty of evidence). 12. Among",
      "extractCut": true
    },
    {
      "id": "sec-024-34-tools-for-systematic-screening-for-tb-disease",
      "number": "3.4",
      "title": "Tools for systematic screening for TB disease among children and adolescents",
      "level": 3,
      "pageStart": 47,
      "pageEnd": 49,
      "labelStart": "35",
      "labelEnd": "37",
      "words": 1239,
      "summary": {
        "text": "Gives recommendations for screening children and adolescents, using symptoms, chest radiography or both for close contacts under 15, and a symptom screen including contact history for children under 10 with HIV. It notes that children accounted for about 12% of TB cases but 16% of deaths in 2019, showing the need for better case detection. It advises placing these tools within national screening and diagnostic algorithms described in the operational handbook.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "among children",
          "heading": true
        },
        {
          "term": "screening tools",
          "heading": true
        },
        {
          "term": "systematic screening",
          "heading": true
        },
        {
          "term": "symptom screening",
          "heading": false
        },
        {
          "term": "children younger",
          "heading": false
        },
        {
          "term": "contacts younger",
          "heading": false
        },
        {
          "term": "symptom screen",
          "heading": false
        },
        {
          "term": "close contacts",
          "heading": false
        }
      ],
      "extract": "among children and adolescents 16. Among individuals younger than 15 years who are close contacts of someone with TB, systematic screening for TB disease should be conducted using a symptom screen including any one of cough, fever or poor weight gain; or chest radiography; or both (new recommendation: strong recommendation, moderate to low certainty of evidence for test accuracy). 17. Among children younger than 10",
      "extractCut": true
    },
    {
      "id": "sec-025-4-monitoring-and-evaluation",
      "number": "4",
      "title": "Monitoring and evaluation",
      "level": 2,
      "pageStart": 49,
      "pageEnd": 49,
      "labelStart": "37",
      "labelEnd": "37",
      "words": 259,
      "summary": {
        "text": "Explains that planning TB screening requires knowing local TB epidemiology, using prevalence surveys or notification data alongside risk factors. It advises monitoring in high-burden settings such as prisons and allows screening to stop when the burden stays low, with surveillance continuing.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "monitoring",
          "heading": true
        },
        {
          "term": "evaluation",
          "heading": true
        },
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "prevalence",
          "heading": false
        },
        {
          "term": "surveillance",
          "heading": false
        },
        {
          "term": "alongside",
          "heading": false
        },
        {
          "term": "surveys",
          "heading": false
        }
      ],
      "extract": "4. Monitoring and evaluation In this section, we consider the monitoring and evaluation required to support the implementation of TB screening programmes. The operational handbook contains more details about the monitoring, surveillance and evaluation of TB screening interventions (7). When considering implementing screening in the general population, it is important to know the epidemiology of TB and the prevalence",
      "extractCut": true
    },
    {
      "id": "sec-026-41-indicators",
      "number": "4.1",
      "title": "Indicators",
      "level": 3,
      "pageStart": 49,
      "pageEnd": 50,
      "labelStart": "37",
      "labelEnd": "38",
      "words": 292,
      "summary": {
        "text": "Lists indicators for monitoring TB screening in each risk group, from numbers eligible and screened to diagnoses, number needed to screen, initial defaulters and treatment outcomes. It notes the value of disaggregation and the difficulty of estimating eligible populations in community outreach.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "people diagnosed",
          "heading": false
        },
        {
          "term": "undergoing diagnostic",
          "heading": false
        },
        {
          "term": "diagnostic investigation",
          "heading": false
        },
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "screened",
          "heading": false
        },
        {
          "term": "risk group",
          "heading": false
        },
        {
          "term": "eligible",
          "heading": false
        },
        {
          "term": "number",
          "heading": false
        }
      ],
      "extract": "Continued monitoring can help programme managers assess the performance of the TB screening components that are within their purview. The following indicators should be considered for each targeted risk group: 1. the number of people eligible for screening; 2. the number of people screened (considering the first screening and second screening separately, if applicable); 3. the proportion of those eligible for",
      "extractCut": true
    },
    {
      "id": "sec-027-42-routines-for-recording-and-reporting",
      "number": "4.2",
      "title": "Routines for recording and reporting",
      "level": 3,
      "pageStart": 50,
      "pageEnd": 50,
      "labelStart": "38",
      "labelEnd": "38",
      "words": 249,
      "summary": {
        "text": "Describes the minimum recording and reporting needed for TB screening indicators, preferably electronic, including logs of people screened and registers of people with presumptive TB. It recommends adding fields to laboratory and treatment registers showing whether patients were found through screening and their risk group.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "patient belongs",
          "heading": false
        },
        {
          "term": "individual-level information",
          "heading": false
        },
        {
          "term": "risk group",
          "heading": false
        },
        {
          "term": "register",
          "heading": false
        },
        {
          "term": "through screening",
          "heading": false
        },
        {
          "term": "collect",
          "heading": false
        },
        {
          "term": "recording",
          "heading": true
        }
      ],
      "extract": "In order to obtain the required information for the indicators described above, a TB recording and reporting system needs to include a minimal set of data elements. Although paper-based systems have been used to collect such data, it is now becoming increasingly feasible to collect data electronically, and this should be the standard aspired to for monitoring TB screening activities. The following strategies can be",
      "extractCut": true
    },
    {
      "id": "sec-028-43-programmatic-evaluations",
      "number": "4.3",
      "title": "Programmatic evaluations",
      "level": 3,
      "pageStart": 50,
      "pageEnd": 51,
      "labelStart": "38",
      "labelEnd": "39",
      "words": 207,
      "summary": {
        "text": "Explains that screening yield may fall over time, so indicators and choices of risk groups, approaches and intervals should be reassessed, with stopping criteria set in advance. It notes that unexpected indicator results may call for special assessments of barriers to screening.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening approach",
          "heading": false
        },
        {
          "term": "nns",
          "heading": false
        },
        {
          "term": "yield",
          "heading": false
        },
        {
          "term": "presumptive",
          "heading": false
        },
        {
          "term": "reduction",
          "heading": false
        },
        {
          "term": "changes",
          "heading": false
        }
      ],
      "extract": "A successful screening programme may lead to a diminishing yield, at least if the risk group is a fixed population. Over time, changes in the background burden of TB, as well as changes in the profile of TB patients in the community (e.g. a trend towards fewer patients with symptomatic TB) can lead to a reduction in the yield from screening, an increase in the NNS, a reduction in cost–effectiveness and a change in",
      "extractCut": true
    },
    {
      "id": "sec-029-44-initial-calibration-for-computer-aided-detect",
      "number": "4.4",
      "title": "Initial calibration for computer-aided detection technologies",
      "level": 3,
      "pageStart": 51,
      "pageEnd": 53,
      "labelStart": "39",
      "labelEnd": "41",
      "words": 74,
      "summary": {
        "text": "Advises local calibration of computer-aided detection score thresholds and ongoing monitoring of its performance against human readers and bacteriological results.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "calibration",
          "heading": true
        },
        {
          "term": "cad",
          "heading": false
        },
        {
          "term": "technologies",
          "heading": true
        }
      ],
      "extract": "technologies When CAD is implemented, local calibration is advised to customize the score thresholds to the requirements of the programme (see the operational handbook for more details about how this can be done) (7). After this initial calibration, ongoing monitoring and analysis of CAD performance should be carried out to assess the correlation with human readers’ interpretations and with bacteriological",
      "extractCut": true
    },
    {
      "id": "sec-030-5-research-gaps",
      "number": "5",
      "title": "Research gaps",
      "level": 2,
      "pageStart": 53,
      "pageEnd": 53,
      "labelStart": "41",
      "labelEnd": "41",
      "words": 3,
      "summary": {
        "text": "A section heading for the chapter on research gaps.",
        "status": "draft"
      },
      "keywords": [],
      "extract": "5. Research gaps",
      "extractCut": false
    },
    {
      "id": "sec-031-51-screening-for-tb-in-targeted-populations",
      "number": "5.1",
      "title": "Screening for TB in targeted populations",
      "level": 3,
      "pageStart": 53,
      "pageEnd": 54,
      "labelStart": "41",
      "labelEnd": "42",
      "words": 644,
      "summary": {
        "text": "Identifies research needs on population-wide and targeted TB screening, including trials of effects on individual and population outcomes, implementation choices and long-term cost-effectiveness. It calls for carefully designed observational studies of community screening and more evidence on screening frequency and outcomes for high-risk children.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "screening children",
          "heading": false
        },
        {
          "term": "well-designed clinical",
          "heading": false
        },
        {
          "term": "patient-important outcomes",
          "heading": false
        },
        {
          "term": "art clinics",
          "heading": false
        },
        {
          "term": "mwrds",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "cost effectiveness",
          "heading": false
        }
      ],
      "extract": "5.1.1 The general population and high-risk groups Well-designed trials and rigorous quasi-experimental studies in different settings are required to investigate the effects of population-wide systematic screening for TB on individual-level outcomes (diagnostic delay, treatment outcomes, costs to patients, social consequences) and population- level outcomes (TB prevalence, incidence, transmission), as well as to",
      "extractCut": true
    },
    {
      "id": "sec-032-52-tools-for-screening-for-tb",
      "number": "5.2",
      "title": "Tools for screening for TB",
      "level": 3,
      "pageStart": 54,
      "pageEnd": 55,
      "labelStart": "42",
      "labelEnd": "43",
      "words": 223,
      "summary": {
        "text": "Lists research gaps on screening tools, including CAD performance across patient groups, user acceptability and CAD for children. It also calls for studies of higher C-reactive protein cut-offs in people with HIV and of complete screening and diagnostic algorithms against patient outcomes.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cad programmes",
          "heading": false
        },
        {
          "term": "screening",
          "heading": true
        },
        {
          "term": "crp",
          "heading": false
        },
        {
          "term": "cxr",
          "heading": false
        },
        {
          "term": "research",
          "heading": false
        },
        {
          "term": "algorithms",
          "heading": false
        },
        {
          "term": "status",
          "heading": false
        }
      ],
      "extract": "5.2.1 Computer-aided detection Further evidence is needed about the performance of CAD software stratified according to the characteristics of the individual being evaluated (e.g. by smear status, HIV status, age cohort, history of TB, smoking status, sex) to allow for better setting-specific and patient-specific calibration of CAD programmes. More research on users’ perspectives is needed about CAD technologies in",
      "extractCut": true
    },
    {
      "id": "sec-033-53-operational-research",
      "number": "5.3",
      "title": "Operational research",
      "level": 3,
      "pageStart": 55,
      "pageEnd": 57,
      "labelStart": "43",
      "labelEnd": "45",
      "words": 137,
      "summary": {
        "text": "Suggests operational research topics for TB screening programmes, such as algorithm performance, acceptability, cost-effectiveness and local CAD calibration, and calls for larger randomized trials.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "cost effectiveness",
          "heading": false
        },
        {
          "term": "operational",
          "heading": true
        },
        {
          "term": "research",
          "heading": true
        },
        {
          "term": "screening",
          "heading": false
        },
        {
          "term": "cad",
          "heading": false
        }
      ],
      "extract": "Standard monitoring and evaluation procedures may be complemented by operational research aimed at improving the performance of screening in the local setting as well as research aimed at improving the global evidence base for screening. Topics that may be explored include: • assessing the accuracy and performance of different algorithms for screening and diagnosis; • identifying operational challenges and",
      "extractCut": true
    },
    {
      "id": "sec-034-6-references",
      "number": "6",
      "title": "References",
      "level": 2,
      "pageStart": 57,
      "pageEnd": 62,
      "labelStart": "45",
      "labelEnd": "50",
      "words": 2323,
      "summary": {
        "text": "The reference list for the WHO TB screening guidelines, citing WHO reports, handbooks and policies and research studies on TB screening and diagnosis.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "accessed february",
          "heading": false
        },
        {
          "term": "infect dis",
          "heading": false
        },
        {
          "term": "lancet infect",
          "heading": false
        },
        {
          "term": "int infect",
          "heading": false
        },
        {
          "term": "bmc infect",
          "heading": false
        },
        {
          "term": "lung dis",
          "heading": false
        },
        {
          "term": "int tuberc",
          "heading": false
        },
        {
          "term": "active tuberculosis",
          "heading": false
        }
      ],
      "extract": "1. Global tuberculosis report 2020. Geneva: World Health Organization; 2020 (https://apps.who.int/iris/ bitstream/handle/10665/336069/9789240013131-eng.pdf, accessed 19 February 2021). 2. Uplekar M, Weil D, Lönnroth K, Jaramillo E, Lienhardt C, Dias HM, et al. WHO’s new End TB Strategy. Lancet. 2015;385:1799–801. doi:10.1016/s0140–6736(15)60570–0. 3. The End TB Strategy [website]. Geneva: World Health Organization;",
      "extractCut": true
    },
    {
      "id": "sec-035-summary-of-changes-to-existing-recommendations",
      "number": null,
      "title": "Summary of changes to existing recommendations",
      "level": 3,
      "pageStart": 62,
      "pageEnd": 63,
      "labelStart": "50",
      "labelEnd": "51",
      "words": 382,
      "summary": {
        "text": "A table comparing 2013 and 2021 TB screening recommendations for groups such as household contacts, people with HIV, silica-exposed workers, prisoners and the general population in high-prevalence areas. It shows updated wording and evidence ratings, with prison screening strengthened from a conditional to a strong recommendation.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "low-quality evidence",
          "heading": false
        },
        {
          "term": "untreated fibrotic",
          "heading": false
        },
        {
          "term": "systematic screening",
          "heading": false
        },
        {
          "term": "penitentiary institutions",
          "heading": false
        },
        {
          "term": "silica exposure",
          "heading": false
        },
        {
          "term": "household contacts",
          "heading": false
        }
      ],
      "extract": "2013 Recommendation 2021 Recommendation Household contacts and other close contacts should be systematically screened for active TB (strong recommendation, very low- quality evidence). Household contacts and other close contacts of individuals with TB should be systematically screened for TB disease (strong recommendation, moderate certainty of evidence). People living with HIV should be systematically screened for",
      "extractCut": true
    },
    {
      "id": "sec-036-supplementary-table",
      "number": null,
      "title": "Supplementary Table",
      "level": 2,
      "pageStart": 63,
      "pageEnd": 68,
      "labelStart": "51",
      "labelEnd": "56",
      "words": 246,
      "summary": {
        "text": "A supplementary table continuing the comparison of 2013 and 2021 recommendations, for marginalized groups with poor access to care and for people living with HIV, followed by WHO Global Tuberculosis Programme contact details.",
        "status": "draft"
      },
      "keywords": [
        {
          "term": "conditional recommendation",
          "heading": false
        },
        {
          "term": "strong recommendation",
          "heading": false
        },
        {
          "term": "night sweats",
          "heading": false
        },
        {
          "term": "indigenous populations",
          "heading": false
        },
        {
          "term": "adolescents living",
          "heading": false
        },
        {
          "term": "people living",
          "heading": false
        },
        {
          "term": "weight loss",
          "heading": false
        },
        {
          "term": "current cough",
          "heading": false
        }
      ],
      "extract": "2013 Recommendation 2021 Recommendation Systematic screening for active TB may be considered also for other subpopulations that have very poor access to health care, such as people living in urban slums, homeless people, people living in remote areas with poor access to health care, and other vulnerable or marginalized groups including some indigenous populations, migrants and refugees (conditional recommendation,",
      "extractCut": true
    }
  ],
  "checks": {
    "tocAlignment": {
      "listed_not_found": {
        "count": 0,
        "items": []
      },
      "found_not_listed": {
        "count": 0,
        "items": []
      },
      "page_mismatch": {
        "count": 0,
        "items": []
      }
    },
    "figureSequenceGaps": [],
    "pageLabelConflicts": {
      "count": 0,
      "items": []
    }
  },
  "withheld": false,
  "keywords": [
    {
      "term": "screening people",
      "heading": true
    },
    {
      "term": "screening systematic",
      "heading": true
    },
    {
      "term": "screening among",
      "heading": true
    },
    {
      "term": "screening population",
      "heading": true
    },
    {
      "term": "tuberculosis screening",
      "heading": false
    },
    {
      "term": "symptom screening",
      "heading": false
    },
    {
      "term": "screening conducted",
      "heading": false
    },
    {
      "term": "screening tools",
      "heading": true
    },
    {
      "term": "screening recommendations",
      "heading": true
    },
    {
      "term": "screening children",
      "heading": true
    },
    {
      "term": "screening test",
      "heading": false
    },
    {
      "term": "screening algorithms",
      "heading": false
    }
  ],
  "pageLabels": [
    {
      "physical": 1,
      "label": "a",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 2,
      "label": "b",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 3,
      "label": "i",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 4,
      "label": "ii",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 5,
      "label": "iii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 6,
      "label": "iv",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 7,
      "label": "v",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 8,
      "label": "vi",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 9,
      "label": "vii",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 10,
      "label": "viii",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 11,
      "label": "ix",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 12,
      "label": "x",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 13,
      "label": "1",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 14,
      "label": "2",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 15,
      "label": "3",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 16,
      "label": "4",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 17,
      "label": "5",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 18,
      "label": "6",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 19,
      "label": "7",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 20,
      "label": "8",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 21,
      "label": "9",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 22,
      "label": "10",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 23,
      "label": "11",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 24,
      "label": "12",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 25,
      "label": "13",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 26,
      "label": "14",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 27,
      "label": "15",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 28,
      "label": "16",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 29,
      "label": "17",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 30,
      "label": "18",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 31,
      "label": "19",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 32,
      "label": "20",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 33,
      "label": "21",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 34,
      "label": "22",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 35,
      "label": "23",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 36,
      "label": "24",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 37,
      "label": "25",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 38,
      "label": "26",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 39,
      "label": "27",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 40,
      "label": "28",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 41,
      "label": "29",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 42,
      "label": "30",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 43,
      "label": "31",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 44,
      "label": "32",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 45,
      "label": "33",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 46,
      "label": "34",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 47,
      "label": "35",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 48,
      "label": "36",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 49,
      "label": "37",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 50,
      "label": "38",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 51,
      "label": "39",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 52,
      "label": "40",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 53,
      "label": "41",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 54,
      "label": "42",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 55,
      "label": "43",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 56,
      "label": "44",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 57,
      "label": "45",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 58,
      "label": "46",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 59,
      "label": "47",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 60,
      "label": "48",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 61,
      "label": "49",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 62,
      "label": "50",
      "source": "printed",
      "confidence": 0.85
    },
    {
      "physical": 63,
      "label": "51",
      "source": "printed",
      "confidence": 1
    },
    {
      "physical": 64,
      "label": "52",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 65,
      "label": "53",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 66,
      "label": "54",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 67,
      "label": "55",
      "source": "pdf-labels",
      "confidence": 0.7
    },
    {
      "physical": 68,
      "label": "56",
      "source": "pdf-labels",
      "confidence": 0.7
    }
  ],
  "figures": [
    {
      "kind": "table",
      "number": "1",
      "title": "Recommendations in the WHO consolidated guidelines on tuberculosis",
      "page": 14,
      "pageLabel": "2",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "box",
      "number": "1",
      "title": "Main changes to the guidance in the current update",
      "page": 16,
      "pageLabel": "4",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "figure",
      "number": "1",
      "title": "Conceptual framework for the 2021 WHO update to guidelines for systematic",
      "page": 19,
      "pageLabel": "7",
      "confidence": 0.9,
      "evidence": [
        "referenced",
        "in-sequence",
        "graphic"
      ]
    },
    {
      "kind": "table",
      "number": "2",
      "title": "Risk factors for tuberculosis (TB) to be considered when prioritizing TB",
      "page": 32,
      "pageLabel": "20",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "3",
      "title": "Diagnostic accuracy of symptoms, chest radiography, and molecular WHO-",
      "page": 36,
      "pageLabel": "24",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "4",
      "title": "Sensitivity and specificity ranges of computer-aided detection software",
      "page": 39,
      "pageLabel": "27",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "5",
      "title": "When used alone, the W4SS was found to have its lowest sensitivity among outpatients on",
      "page": 41,
      "pageLabel": "29",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "6",
      "title": "Diagnostic accuracy of C-reactive protein using a cut-off > 5 mg/L among",
      "page": 43,
      "pageLabel": "31",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "7",
      "title": "Diagnostic accuracy among different subpopulations of people living with",
      "page": 44,
      "pageLabel": "32",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    },
    {
      "kind": "table",
      "number": "8",
      "title": "Diagnostic accuracy of molecular WHO-recommended rapid diagnostic",
      "page": 45,
      "pageLabel": "33",
      "confidence": 0.8,
      "evidence": [
        "referenced",
        "in-sequence"
      ]
    }
  ],
  "images": [
    {
      "id": "vfig-p019",
      "file": "figures/vfig-p019.webp",
      "page": 19,
      "shows": [
        "Figure 1"
      ],
      "narratives": {
        "en": "Fig. 1, a conceptual framework (logic model) for systematic screening for TB, in four columns: Inputs (political and stakeholder engagement, financial resources, human resources, equipment and supplies) feed Activities (screening interventions and activities, including health centre-, community- and household-based activities). These lead to individual-level outcomes (increased TB knowledge, awareness and care-seeking; increased diagnosis and treatment initiation; reduced diagnostic delay; improved treatment outcomes; reduced costs and adverse social consequences) and population-level outcomes (reduced time of infectiousness and prevalence of infectious cases, reduced transmission, and reduced incidence and prevalence of TB).",
        "ar": "الشكل 1، إطار مفاهيمي (نموذج منطقي) للتحري المنهجي عن السل، في أربعة أعمدة: المدخلات (إشراك الجهات السياسية وأصحاب المصلحة، والموارد المالية، والموارد البشرية، والمعدات والإمدادات) تغذي الأنشطة (تدخلات وأنشطة التحري، بما فيها الأنشطة في المراكز الصحية والمجتمعات المحلية والأسر المعيشية). وتؤدي هذه إلى نتائج على مستوى الفرد (زيادة المعرفة بالسل والوعي به والتماس الرعاية؛ وزيادة التشخيص وبدء العلاج؛ وتقليل التأخر في التشخيص؛ وتحسين نتائج العلاج؛ وخفض التكاليف والعواقب الاجتماعية الضارة) ونتائج على مستوى السكان (تقليل مدة العدوى وانتشار الحالات المعدية، وتقليل سريان المرض، وخفض معدل الإصابة بالسل وانتشاره).",
        "zh": "图1，结核病系统筛查的概念框架（逻辑模型），分为四栏：投入（政治和利益攸关方参与、财政资源、人力资源、设备和用品）支撑活动（筛查干预措施和活动，包括以卫生中心、社区和家庭为基础的活动）。这些活动带来个人层面的结果（结核病知识、意识和求医行为增加；诊断和治疗启动增加；诊断延误减少；治疗结果改善；费用和不良社会后果减少）以及人群层面的结果（传染期和传染性病例患病率降低、传播减少、结核病发病率和患病率降低）。",
        "es": "Figura 1, marco conceptual (modelo lógico) del cribado sistemático de la TB, en cuatro columnas: los insumos (participación política y de las partes interesadas, recursos financieros, recursos humanos, equipos y suministros) alimentan las actividades (intervenciones y actividades de cribado, incluidas actividades en centros de salud, comunidades y hogares). Estas conducen a resultados individuales (mayor conocimiento y concienciación sobre la TB y búsqueda de atención; aumento del diagnóstico y del inicio del tratamiento; menor retraso diagnóstico; mejores resultados del tratamiento; menores costos y consecuencias sociales adversas) y a resultados poblacionales (menor tiempo de infecciosidad y prevalencia de casos infecciosos, menor transmisión y menor incidencia y prevalencia de la TB).",
        "fr": "Figure 1, cadre conceptuel (modèle logique) du dépistage systématique de la tuberculose, en quatre colonnes : les intrants (engagement politique et des parties prenantes, ressources financières, ressources humaines, équipements et fournitures) alimentent les activités (interventions et activités de dépistage, y compris dans les centres de santé, les communautés et les ménages). Celles-ci conduisent à des résultats individuels (meilleure connaissance de la tuberculose, sensibilisation et recours aux soins ; augmentation du diagnostic et de la mise sous traitement ; réduction du retard diagnostique ; amélioration des résultats thérapeutiques ; réduction des coûts et des conséquences sociales néfastes) et à des résultats populationnels (réduction de la durée de contagiosité et de la prévalence des cas contagieux, réduction de la transmission, et baisse de l’incidence et de la prévalence de la tuberculose).",
        "ru": "Рис. 1 — концептуальная основа (логическая модель) систематического скрининга на ТБ в четырёх столбцах: ресурсы (участие политических кругов и заинтересованных сторон, финансовые ресурсы, кадровые ресурсы, оборудование и расходные материалы) обеспечивают мероприятия (скрининговые вмешательства и мероприятия, в том числе в медицинских центрах, общинах и домохозяйствах). Они ведут к результатам на индивидуальном уровне (рост знаний о ТБ, осведомлённости и обращаемости за помощью; увеличение диагностики и начала лечения; сокращение задержки диагностики; улучшение исходов лечения; снижение затрат и неблагоприятных социальных последствий) и на уровне населения (сокращение периода заразности и распространённости заразных случаев, снижение передачи, снижение заболеваемости ТБ и её распространённости)."
      },
      "state": "draft"
    },
    {
      "id": "img-p068-1",
      "file": "images/img-p068-1.webp",
      "page": 68,
      "narratives": {
        "en": "ISBN barcode for 9789240022676.",
        "ar": "رمز شريطي للرقم الدولي المعياري للكتاب ISBN 9789240022676.",
        "zh": "ISBN条形码：9789240022676。",
        "es": "Código de barras del ISBN 9789240022676.",
        "fr": "Code-barres ISBN 9789240022676.",
        "ru": "Штрихкод ISBN 9789240022676."
      },
      "state": "draft"
    }
  ],
  "tables": [
    {
      "label": "Table 1",
      "caption": "Table 1. Recommendations in the WHO consolidated guidelines on tuberculosis. Module 2: screening – systematic screening for tuberculosis disease, 2021",
      "pages": [
        14,
        15,
        16
      ],
      "columns": [
        {
          "titles": "No."
        },
        {
          "titles": "Recommendation"
        }
      ],
      "rows": [
        [
          "Screening for TB in targeted populations",
          ""
        ],
        [
          "1",
          "Systematic screening for TB disease may be conducted among the general population in areas with an estimated TB prevalence of 0.5% or higher (updated recommendation: conditional recommendation, low certainty of evidence)."
        ],
        [
          "2",
          "Systematic screening for TB disease may be conducted among subpopulations with structural risk factors for TB. These include urban poor communities, homeless communities, communities in remote or isolated areas, indigenous populations, migrants, refugees, internally displaced persons and other vulnerable or marginalized groups with limited access to health care (existing recommendation: conditional recommendation, very low certainty of evidence)."
        ],
        [
          "3",
          "People living with HIV should be systematically screened for TB disease at each visit to a health facility (existing recommendation: strong recommendation, very low certainty of evidence)."
        ],
        [
          "4",
          "Household contacts and other close contacts of individuals with TB disease should be systematically screened for TB disease (updated recommendation: strong recommendation, moderate certainty of evidence)."
        ],
        [
          "5",
          "Systematic screening for TB disease should be conducted in prisons and penitentiary institutions (updated recommendation: strong recommendation, very low certainty of evidence)."
        ],
        [
          "6",
          "Current and former workers in workplaces with silica exposure should be systematically screened for TB disease (existing recommendation: strong recommendation, low certainty of evidence)."
        ],
        [
          "7",
          "In settings where the TB prevalence in the general population is 100/100 000 population or higher, systematic screening for TB disease may be conducted among people with a risk factor for TB who are either seeking health care or who are already in care (existing recommendation: conditional recommendation, very low certainty of evidence)."
        ],
        [
          "8",
          "People with an untreated fibrotic lesion seen on chest X-ray may be systematically screened for TB disease (existing recommendation: conditional recommendation, very low certainty of evidence)."
        ],
        [
          "Tools for screening for TB",
          ""
        ],
        [
          "9",
          "Among individuals aged 15 years and older in populations in which TB screening is recommended, systematic screening for TB disease may be conducted using a symptom screen, chest X-ray or molecular WHO-recommended rapid diagnostic tests, alone or in combination (new recommendation: conditional recommendation, very low certainty of evidence for test accuracy)."
        ],
        [
          "10",
          "Among individuals aged 15 years and older in populations in which TB screening is recommended, computer-aided detection software programmes may be used in place of human readers for interpreting digital chest X-rays for screening and triage for TB disease (new recommendation: conditional recommendation, low certainty of evidence)."
        ],
        [
          "11",
          "Among adults and adolescents living with HIV, systematic screening for TB disease should be conducted using the WHO-recommended four symptom screen and those who report any one of the symptoms of current cough, fever, weight loss or night sweats may have TB and should be evaluated for TB and other diseases (existing recommendation: strong recommendation, moderate certainty of evidence)."
        ],
        [
          "12",
          "Among adults and adolescents living with HIV, C-reactive protein using a cut-off of >5mg/L may be used to screen for TB disease (new recommendation: conditional recommendation, low certainty of evidence for test accuracy)."
        ],
        [
          "13",
          "Among adults and adolescents living with HIV, chest X-ray may be used to screen for TB disease (new recommendation: conditional recommendation, moderate certainty of evidence for test accuracy)."
        ],
        [
          "14",
          "Among adults and adolescents living with HIV, molecular WHO-recommended rapid diagnostic tests may be used to screen for TB disease (new recommendation: conditional recommendation, moderate certainty of evidence for test accuracy)."
        ],
        [
          "15",
          "Adult and adolescent inpatients with HIV in medical wards where the TB prevalence is > 10% should be tested systematically for TB disease with a molecular WHO- recommended rapid diagnostic test (new recommendation: strong recommendation, moderate certainty of evidence for test accuracy)."
        ],
        [
          "16",
          "Among individuals younger than 15 years who are close contacts of someone with TB, systematic screening for TB disease should be conducted using a symptom screen including any one of cough, fever or poor weight gain; or chest radiography; or both (new recommendation: strong recommendation, moderate to low certainty of evidence for test accuracy)."
        ],
        [
          "17",
          "Among children younger than 10 years who are living with HIV, systematic screening for TB disease should be conducted using a symptom screen including any one of current cough, fever, poor weight gain or close contact with a TB patient (new recommendation: strong recommendation, low certainty of evidence for test accuracy)."
        ]
      ],
      "notes": "TB: tuberculosis. Column headers are not printed; “No.” and “Recommendation” are supplied. The section header “Screening for TB in targeted populations” is repeated at the top of page 15 and is not repeated here.",
      "narratives": {
        "en": "The table lists the 17 recommendations of the 2021 WHO guidelines on systematic screening for TB disease, grouped into screening in targeted populations (1–8) and tools for screening (9–17). Each recommendation is followed by its status (new, updated or existing), its strength and the certainty of the evidence.",
        "ar": "يسرد الجدول التوصيات السبع عشرة الواردة في المبادئ التوجيهية للمنظمة لعام 2021 بشأن التحري المنهجي عن مرض السل، مقسمة إلى التحري في الفئات السكانية المستهدفة (1–8) وأدوات التحري (9–17). وتُتبع كل توصية بحالتها (جديدة أو محدَّثة أو قائمة) وقوتها ودرجة اليقين في البيّنات.",
        "zh": "本表列出了世卫组织2021年结核病系统性筛查指南中的17项建议，分为目标人群筛查（1–8）和筛查工具（9–17）两部分。每项建议后注明其状态（新的、更新的或现有的）、建议强度以及证据确定性。",
        "es": "El cuadro enumera las 17 recomendaciones de las directrices de la OMS de 2021 sobre el cribado sistemático de la enfermedad tuberculosa, agrupadas en cribado en poblaciones destinatarias (1–8) e instrumentos de cribado (9–17). Cada recomendación va seguida de su carácter (nueva, actualizada o existente), su fuerza y la certeza de la evidencia.",
        "fr": "Le tableau présente les 17 recommandations des lignes directrices 2021 de l’OMS sur le dépistage systématique de la tuberculose maladie, regroupées en dépistage dans les populations cibles (1–8) et outils de dépistage (9–17). Chaque recommandation est suivie de son statut (nouvelle, actualisée ou existante), de sa force et du degré de certitude des données.",
        "ru": "В таблице перечислены 17 рекомендаций руководства ВОЗ 2021 г. по систематическому скринингу на туберкулёз, сгруппированных по скринингу в целевых группах населения (1–8) и инструментам скрининга (9–17). После каждой рекомендации указаны её статус (новая, обновлённая или существующая), сила и степень достоверности данных."
      },
      "csv": "tables/table-1.csv"
    },
    {
      "label": "Table 2",
      "caption": "Table 2. Risk factors for tuberculosis (TB) to be considered when prioritizing TB screening among people attending for health care",
      "pages": [
        32,
        33
      ],
      "columns": [
        {
          "titles": "Risk factor"
        },
        {
          "titles": "Risk of TB or of poor outcomes"
        }
      ],
      "rows": [
        [
          "Fibrotic lesions on chest X-ray",
          "Studies have shown an increased risk of developing TB disease among individuals with fibrotic lesions identified on chest X-ray but who are not diagnosed with TB disease.a"
        ],
        [
          "Diabetes mellitus (DM)",
          "Systematic reviews have found that the risk of TB for patients with DM ranges from 1.5 to 2.0 to 3.1, with a decreasing risk in patients with well-controlled DM. Patients with DM were also at an increased risk of relapse, treatment failure and death.b"
        ],
        [
          "Previous TB",
          "Patients with a history of TB are at increased risk of subsequent TB episodes, poor outcomes and developing drug-resistant TB.c"
        ],
        [
          "Chronic lung disease",
          "Studies have found hazard ratios for developing TB among individuals with COPD ranging from 2.5 in China to 3.0 in Sweden.d"
        ],
        [
          "Smoking",
          "Systematic reviews have found that people who smoke or who have a history of smoking have an increased risk of TB, with the RR ranging from 1.5 to 2.0 to 3.3; smokers are also at an increased risk of drug-resistant TB and poor outcomes from TB, including relapse and death.e"
        ],
        [
          "Alcohol use disorder",
          "Systematic reviews have found a 1.35 to 1.9 RR associated with alcohol use and a 3 to 3.33 RR associated with alcohol use disorder, as well as increased risks of treatment failure and development of drug-resistant TB. An exposure–response analysis showed that for every 10–20 g of daily alcohol intake, there was a 12% increase in TB risk.f"
        ],
        [
          "Substance use disorder",
          "People with substance use disorder are at increased risks of treatment failure, development of drug resistance, and mortality from TB due to low adherence and coincident clinical, socioeconomic and structural risk factors.g"
        ],
        [
          "Malnourishment",
          "A systematic review found that lower BMI is associated with an increased risk of TB, with a reduction in TB incidence of 13.8% (95% confidence interval: 13.4–14.2) per unit increase in BMI within the range 18.5–30 kg/m2. There are multiple pathways by which undernourishment can increase the risk of TB, including cell-mediated immunity and micronutrient deficiency, and other conditions can increase the risk of malnourishment and TB, including mental health and substance use disorders.h"
        ],
        [
          "Pregnancy",
          "A national registry study found IRRs for TB in pregnant women of 1.4 and of 1.9 for postpartum women compared with non-pregnant women. TB in pregnancy is associated with adverse outcomes and complications during birth. These outcomes include a roughly 2-fold increased risk of premature birth, low birthweight and intrauterine growth retardation, and a 6-fold increased risk of perinatal death.i"
        ],
        [
          "Immunocompromising conditions (organ transplant, renal failure, dialysis)",
          "Systematic reviews have found that patients with immunosuppression for reasons other than HIV, including those undergoing organ transplantation or haemodialysis and those with renal failure, have a greatly increased risk of TB: one study found that the incidence of TB is 20–74 times higher in organ transplant patients compared with the general population; one study found that the incidence of TB is 10–25 times higher in dialyzed individuals compared with the general population; and one cohort study found that the incidence of TB is 100 times greater in persons undergoing dialysis compared with general population.j"
        ],
        [
          "Health care workers",
          "A systematic review found the IRR of TB disease for health care workers was 2.94 compared with the general population.k"
        ]
      ],
      "notes": "BMI: body mass index; COPD: chronic obstructive pulmonary disease; DM: diabetes mellitus; IRR: incidence rate ratio; RR: relative risk. a Ferebee SH. Controlled chemoprophylaxis trials in tuberculosis. A general review. Bibl Tuberc. 1970;26:28–106. Meijer J, Barnett GD, Kubík A, Stýblo K. Identification des sources d’infection [Identification of sources of infection]. Bull Int Union Tuberc. 1971;45:5–54. Okada K, Onozaki I, Yamada N, Yoshiyama T, Miura T, Saint S, et al. Epidemiological impact of mass tuberculosis screening: a 2-year follow-up after a national prevalence survey. Int J Tuberc Lung Dis. 2012;16:1619–24. doi:10.5588/ijtld.12.0201. Gao L, Li X, Liu J, Wang X, Lu W, Bai L, et al. Incidence of active tuberculosis in individuals with latent tuberculosis infection in rural China: follow-up results of a population-based, multicentre, prospective cohort study. Lancet Infect Dis. 2017;17:1053–61. doi:10.1016/s1473–3099(17)30402–4. b Hayashi S, Chandramohan D. Risk of active tuberculosis among people with diabetes mellitus: systematic review and meta-analysis. Trop Med Int Health. 2018;23:1058–70. doi:10.1111/tmi.13133. Al-Rifai RH, Pearson F, Critchley JA, Abu-Raddad LJ. Association between diabetes mellitus and active tuberculosis: a systematic review and meta-analysis. PLOS ONE. 2017;12:e0187967. doi:10.1371/journal.pone.0187967. Harries AD, Kumar AM, Satyanarayana S, Lin Y, Zachariah R, Lönnroth K, et al. Addressing diabetes mellitus as part of the strategy for ending TB. Trans R Soc Trop Med Hyg. 2016;110:173–9. doi:10.1093/trstmh/trv111. Baker MA, Harries AD, Jeon CY, Hart JE, Kapur A, Lönnroth K, et al. The impact of diabetes on tuberculosis treatment outcomes: a systematic review. BMC Med. 2011;9:81. doi:10.1186/1741–7015–9-81. c Zignol M, Wright A, Jaramillo E, Nunn P, Raviglione MC. Patients with previously treated tuberculosis no longer neglected. Clin Infect Dis. 2007;44:61–4. doi:10.1086/509328. Lambert ML, Hasker E, Van Deun A, Roberfroid D, Boelaert M, Van der Stuyft P. Recurrence in tuberculosis: relapse or reinfection? Lancet Infect Dis. 2003;3:282–7. doi:10.1016/s1473–3099(03)00607–8. Verver S, Warren RM, Beyers N, Richardson M, van der Spuy GD, Borgdorff MW, et al. Rate of reinfection tuberculosis after successful treatment is higher than rate of new tuberculosis. Am J Respir Crit Care Med. 2005;171:1430–5. doi:10.1164/rccm.200409–1200OC. Osman M, Welte A, Dunbar R, Brown R, Hoddinott G, Hesseling AC, et al. Morbidity and mortality up to 5 years post tuberculosis treatment in South Africa: a pilot study. Int J Infect Dis. 2019;85:57–63. doi:10.1016/j.ijid.2019.05.024. d Inghammar M, Ekbom A, Engström G, Ljungberg B, Romanus V, Löfdahl CG, et al. COPD and the risk of tuberculosis–a population-based cohort study. PLOS ONE. 2010;5:e10138. doi:10.1371/journal.pone.0010138. Lee CH, Lee MC, Shu CC, Lim CS, Wang JY, Lee LN et al. Risk factors for pulmonary tuberculosis in patients with chronic obstructive airway disease in Taiwan: a nationwide cohort study. BMC Infect Dis. 2013;13:194. doi: 10.1186/1471-2334-13-194. e Jayes L, Haslam PL, Gratziou CG, Powell P, Britton J, Vardavas C, et al. SmokeHaz: systematic reviews and meta-analyses of the effects of smoking on respiratory health. Chest. 2016;150:164–79. doi:10.1016/j.chest.2016.03.060. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLOS Med. 2007;4:e20. doi:10.1371/journal.pmed.0040020. Wang MG, Huang WW, Wang Y, Zhang YX, Zhang MM, Wu SQ, et al. Association between tobacco smoking and drug-resistant tuberculosis. Infect Drug Resist. 2018;11:873–87. doi:10.2147/idr.s164596. Alavi-Naini R, Sharifi-Mood B, Metanat M. Association between tuberculosis and smoking. Int J High Risk Behav Addict. 2012;1:71–4. doi:10.5812/ijhrba.5215. f Imtiaz S, Shield KD, Roerecke M, Samokhvalov AV, Lönnroth K, Rehm J. Alcohol consumption as a risk factor for tuberculosis: meta- analyses and burden of disease. Eur Respir J. 2017;50:1700216. doi:10.1183/13993003.00216–2017. Simou E, Britton J, Leonardi-Bee J. Alcohol consumption and risk of tuberculosis: a systematic review and meta-analysis. Int J Tuberc Lung Dis. 2018;22:1277–85. doi:10.5588/ ijtld.18.0092. Rehm J, Samokhvalov AV, Neuman MG, Room R, Parry C, Lönnroth K, et al. The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review. BMC Public Health. 2009;9:450. doi:10.1186/1471–2458–9-450. g Deiss RG, Rodwell TC, Garfein RS. Tuberculosis and illicit drug use: review and update. Clin Infect Dis. 2009;48:72–82. doi:10.1086/594126. Getahun H, Gunneberg C, Sculier D, Verster A, Raviglione M. Tuberculosis and HIV in people who inject drugs: evidence for action for tuberculosis, HIV, prison and harm reduction services. Curr Opin HIV AIDS. 2012;7:345–53. doi:10.1097/COH.0b013e328354bd44. Silva DR, Muñoz-Torrico M, Duarte R, Galvão T, Bonini EH, Arbex FF, et al. Risk factors for tuberculosis: diabetes, smoking, alcohol use, and the use of other drugs. J Bras Pneumol. 2018;44:145–52. doi:10.1590/s1806–37562017000000443. h Lönnroth K, Williams BG, Cegielski P, Dye C. A consistent log-linear relationship between tuberculosis incidence and body mass index. Int J Epidemiol. 2010;39:149–55. doi:10.1093/ije/dyp308. Cegielski JP, McMurray DN. The relationship between malnutrition and tuberculosis: evidence from studies in humans and experimental animals. Int J Tuberc Lung Dis. 2004;8:286–98. i Jonsson J, Kühlmann-Berenzon S, Berggren I, Bruchfeld J. Increased risk of active tuberculosis during pregnancy and postpartum: a register-based cohort study in Sweden. Eur Respir J. 2020;55:1901886. doi:10.1183/13993003.01886–2019. Sugarman J, Colvin C, Moran AC, Oxlade O. Tuberculosis in pregnancy: an estimate of the global burden of disease. Lancet Glob Health. 2014;2:e710–6. doi:10.1016/ s2214–109x(14)70330–4. doi:10.1016/S2214–109X(14)70330–4. Loto OM, Awowole I. Tuberculosis in pregnancy: a review. J Pregnancy. 2012;2012:379271. doi:10.1155/2012/379271. j Muñoz P, Rodríguez C, Bouza E. Mycobacterium tuberculosis infection in recipients of solid organ transplants. Clin Infect Dis. 2005;40:581– 7. doi:10.1086/427692. Moore DA, Lightstone L, Javid B, Friedland JS. High rates of tuberculosis in end-stage renal failure: the impact of international migration. Emerg Infect Dis. 2002;8:77–8. doi:10.3201/eid0801.010017. Moran E, Baharani J, Dedicoat M, Robinson E, Smith G, Bhomra P, et al. Risk factors associated with the development of active tuberculosis among patients with advanced chronic kidney disease. J Infect. 2018;77:291–5. doi:10.1016/j.jinf.2018.06.003. k Uden L, Barber E, Ford N, Cooke GS. Risk of tuberculosis infection and disease for health care workers: an updated meta-analysis. Open Forum Infect Dis. 2017;4:ofx137. doi:10.1093/ofid/ofx137.",
      "narratives": {
        "en": "The table lists 11 clinical and other risk factors to consider when prioritizing TB screening among people attending health care, such as fibrotic lesions on chest X-ray, diabetes, previous TB, smoking, alcohol use disorder and pregnancy. For each it summarizes the evidence on the risk of TB or of poor TB outcomes, with references in footnotes.",
        "ar": "يسرد الجدول 11 عامل خطر سريريًا وغيره ينبغي مراعاتها عند إعطاء الأولوية للتحري عن السل بين المترددين على خدمات الرعاية الصحية، مثل الآفات الليفية في صورة الصدر بالأشعة السينية، والسكري، والإصابة السابقة بالسل، والتدخين، واضطراب تعاطي الكحول، والحمل. ويلخص لكل منها البيّنات المتعلقة بخطر الإصابة بالسل أو بسوء نتائجه، مع المراجع في الحواشي.",
        "zh": "本表列出了在就医人群中确定结核病筛查优先次序时应考虑的11项临床及其他风险因素，如胸部X线纤维化病灶、糖尿病、既往结核病、吸烟、酒精使用障碍和妊娠。对每项因素，表中概述了关于结核病风险或不良结局风险的证据，参考文献见脚注。",
        "es": "El cuadro enumera 11 factores de riesgo clínicos y de otro tipo que deben tenerse en cuenta al priorizar el cribado de la TB entre las personas que acuden a los servicios de salud, como las lesiones fibróticas en la radiografía de tórax, la diabetes, la TB previa, el tabaquismo, el trastorno por consumo de alcohol y el embarazo. Para cada uno resume la evidencia sobre el riesgo de TB o de malos resultados, con las referencias en notas.",
        "fr": "Le tableau présente 11 facteurs de risque, cliniques ou autres, à prendre en compte pour prioriser le dépistage de la tuberculose chez les personnes consultant les services de santé, comme les lésions fibrotiques à la radiographie thoracique, le diabète, des antécédents de tuberculose, le tabagisme, les troubles liés à l’usage de l’alcool et la grossesse. Pour chacun, il résume les données sur le risque de tuberculose ou d’issues défavorables, avec les références en notes.",
        "ru": "В таблице перечислены 11 клинических и иных факторов риска, которые следует учитывать при определении приоритетов скрининга на ТБ среди лиц, обращающихся за медицинской помощью, например фиброзные изменения на рентгенограмме грудной клетки, диабет, ТБ в анамнезе, курение, расстройства, связанные с употреблением алкоголя, и беременность. Для каждого фактора кратко изложены данные о риске ТБ или неблагоприятных исходов со ссылками в сносках."
      },
      "csv": "tables/table-2.csv"
    },
    {
      "label": "Table 3",
      "caption": "Table 3. Diagnostic accuracy of symptoms, chest radiography, and molecular WHO-recommended rapid diagnostic tests for screening for TB disease",
      "pages": [
        36
      ],
      "columns": [
        {
          "titles": "Screening test"
        },
        {
          "titles": "No. of studies (no. of participants)"
        },
        {
          "titles": "Sensitivity"
        },
        {
          "titles": "No. of studies (no. of participants)"
        },
        {
          "titles": "Specificity"
        }
      ],
      "rows": [
        [
          "WHO target product profile",
          "NA",
          "> 0.90",
          "NA",
          "> 0.70"
        ],
        [
          "Prolonged cough (≥ 2 weeks)",
          "40 (6 737)",
          "0.42",
          "40 (1 284 181)",
          "0.94"
        ],
        [
          "Any cough",
          "21 (2 734)",
          "0.51",
          "21 (768 291)",
          "0.88"
        ],
        [
          "Any TB symptom (cough, haemoptysis, fever, night sweats, weight loss)",
          "28 (3 915)",
          "0.71",
          "28 (460 878)",
          "0.64"
        ],
        [
          "Chest radiography (any abnormality)",
          "22 (4 243)",
          "0.94",
          "22 (1 012 752)",
          "0.89"
        ],
        [
          "Chest radiography (suggestive abnormality)",
          "19 (2 152)",
          "0.85",
          "19 (464 818)",
          "0.96"
        ],
        [
          "Molecular WHO-recommended rapid diagnostic test",
          "5 (337)",
          "0.69",
          "5 (8 619)",
          "0.99"
        ]
      ],
      "notes": "NA: not applicable.",
      "narratives": {
        "en": "The table compares the pooled sensitivity and specificity of screening tests for TB disease – cough of different durations, any TB symptom, chest radiography and molecular WHO-recommended rapid diagnostic tests – against the WHO target product profile, with the number of studies and participants behind each estimate.",
        "ar": "يقارن الجدول الحساسية والنوعية المجمعتين لاختبارات التحري عن مرض السل – السعال بمدد مختلفة، وأي عرض من أعراض السل، والتصوير الشعاعي للصدر، والاختبارات الجزيئية التشخيصية السريعة التي توصي بها المنظمة – مقابل المواصفات المستهدفة للمنتج لدى المنظمة، مع عدد الدراسات والمشاركين الذين يستند إليهم كل تقدير.",
        "zh": "本表将各项结核病筛查检测——不同持续时间的咳嗽、任何结核病症状、胸部X线摄影以及世卫组织推荐的分子快速诊断检测——的合并敏感度和特异度与世卫组织目标产品特征进行比较，并列出每项估计所依据的研究数和参与者人数。",
        "es": "El cuadro compara la sensibilidad y la especificidad agrupadas de las pruebas de cribado de la enfermedad tuberculosa – tos de distinta duración, cualquier síntoma de TB, radiografía de tórax y pruebas diagnósticas rápidas moleculares recomendadas por la OMS – con el perfil de producto objetivo de la OMS, con el número de estudios y de participantes en que se basa cada estimación.",
        "fr": "Le tableau compare la sensibilité et la spécificité poolées des tests de dépistage de la tuberculose maladie – toux de durées différentes, tout symptôme de tuberculose, radiographie thoracique et tests moléculaires de diagnostic rapide recommandés par l’OMS – au profil de produit cible de l’OMS, avec le nombre d’études et de participants à l’origine de chaque estimation.",
        "ru": "В таблице объединённые чувствительность и специфичность скрининговых тестов на туберкулёз — кашля разной продолжительности, любого симптома ТБ, рентгенографии грудной клетки и рекомендованных ВОЗ молекулярных экспресс-тестов — сопоставлены с целевым профилем продукта ВОЗ, с указанием числа исследований и участников для каждой оценки."
      },
      "csv": "tables/table-3.csv"
    },
    {
      "label": "Table 4",
      "caption": "Table 4. Sensitivity and specificity ranges of computer-aided detection software and human readers interpreting digital chest radiographs for detection of bacteriologically confirmed TB across three software programmes, from three independent evaluations of the software in a range of populations and settings",
      "pages": [
        39
      ],
      "columns": [
        {
          "titles": "Type of case and type of reader"
        },
        {
          "titles": "Sensitivity",
          "group": "Accuracy estimate range"
        },
        {
          "titles": "Specificity",
          "group": "Accuracy estimate range"
        }
      ],
      "rows": [
        [
          "WHO target product profile",
          "> 0.90",
          "> 0.70"
        ],
        [
          "Screening use case",
          "",
          ""
        ],
        [
          "CAD software",
          "0.90–0.92",
          "0.23–0.66"
        ],
        [
          "CXR with human reader",
          "0.82–0.93",
          "0.14–0.63"
        ],
        [
          "Triage use case",
          "",
          ""
        ],
        [
          "CAD software",
          "0.90–0.91",
          "0.25–0.79"
        ],
        [
          "CXR with human reader",
          "0.89–0.96",
          "0.36–0.63"
        ]
      ],
      "notes": "CAD: computer-aided detection; CXR: chest X-ray.",
      "narratives": {
        "en": "The table gives the ranges of sensitivity and specificity of computer-aided detection (CAD) software and of human readers interpreting digital chest X-rays for bacteriologically confirmed TB, separately for the screening and triage use cases, alongside the WHO target product profile.",
        "ar": "يعرض الجدول نطاقات الحساسية والنوعية لبرمجيات الكشف بمساعدة الحاسوب وللقراء البشريين في تفسير صور الصدر الرقمية بالأشعة السينية للكشف عن السل المؤكد جرثوميًا، بشكل منفصل لحالتي استخدام التحري والفرز، إلى جانب المواصفات المستهدفة للمنتج لدى المنظمة.",
        "zh": "本表列出了计算机辅助检测（CAD）软件和人工阅片者解读数字胸部X线片以检测细菌学确诊结核病的敏感度和特异度范围，按筛查和分诊两种使用情形分别列出，并附世卫组织目标产品特征。",
        "es": "El cuadro presenta los intervalos de sensibilidad y especificidad del software de detección asistida por computadora (DAC) y de los lectores humanos que interpretan radiografías de tórax digitales para la TB confirmada bacteriológicamente, por separado para los usos de cribado y de triaje, junto con el perfil de producto objetivo de la OMS.",
        "fr": "Le tableau présente les fourchettes de sensibilité et de spécificité des logiciels de détection assistée par ordinateur (DAO) et des lecteurs humains interprétant des radiographies thoraciques numériques pour la tuberculose confirmée bactériologiquement, séparément pour les usages de dépistage et de triage, ainsi que le profil de produit cible de l’OMS.",
        "ru": "В таблице приведены диапазоны чувствительности и специфичности программ компьютерной диагностики (CAD) и специалистов, интерпретирующих цифровые рентгенограммы грудной клетки, при выявлении бактериологически подтверждённого ТБ — отдельно для скрининга и сортировки, а также целевой профиль продукта ВОЗ."
      },
      "csv": "tables/table-4.csv"
    },
    {
      "label": "Table 5",
      "caption": "Table 5. Diagnostic accuracy of the WHO-recommended four-symptom screen among different subpopulations of people living with HIV compared with culture as a reference standard",
      "pages": [
        42
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "No. of studies (no. of participants)"
        },
        {
          "titles": "Sensitivity (95% CI)"
        },
        {
          "titles": "Specificity (95% CI)"
        }
      ],
      "rows": [
        [
          "WHO target product profile",
          "NA",
          "> 0.90",
          "> 0.70"
        ],
        [
          "All people living with HIV",
          "23 (16 269)",
          "0.83 (0.74–0.89)",
          "0.38 (0.25–0.53)"
        ],
        [
          "Inpatients",
          "4 (672)",
          "0.96 (0.92–0.98)",
          "0.11 (0.08–0.14)"
        ],
        [
          "Outpatients on ART",
          "9 (4 309)",
          "0.53 (0.36–0.69)",
          "0.70 (0.50–0.85)"
        ],
        [
          "Outpatients not on ART",
          "19 (11 159)",
          "0.84 (0.75–0.90)",
          "0.37 (0.25–0.50)"
        ],
        [
          "CD4 ≤ 200 cells/µL",
          "22 (5 956)",
          "0.86 (0.77–0.92)",
          "0.30 (0.18–0.45)"
        ],
        [
          "Pregnant women living with HIV",
          "8 (1 937)",
          "0.61 (0.39–0.79)",
          "0.58 (0.39–0.75)"
        ]
      ],
      "notes": "ART: antiretroviral treatment; CI: confidence interval; NA: not applicable.",
      "narratives": {
        "en": "The table gives the sensitivity and specificity (95% CI) of the WHO-recommended four-symptom screen (W4SS), compared with culture, for TB among people living with HIV overall and in subpopulations (inpatients, outpatients on and not on ART, CD4 ≤ 200 cells/µL, pregnant women), with the number of studies and participants, against the WHO target product profile.",
        "ar": "يعرض الجدول الحساسية والنوعية (مع فترات ثقة 95%) لـفحص الأعراض الأربعة الذي توصي به المنظمة، مقارنةً بالزرع، في الكشف عن السل لدى المتعايشين مع فيروس العوز المناعي البشري عمومًا وفي فئات فرعية (المرضى الداخليون، والمرضى الخارجيون الذين يتلقون أو لا يتلقون العلاج المضاد للفيروسات القهقرية، ومن لديهم CD4 ≤ 200 خلية/ميكرولتر، والحوامل)، مع عدد الدراسات والمشاركين، مقارنةً بالمواصفات المستهدفة للمنتج لدى المنظمة.",
        "zh": "本表列出了世卫组织推荐的四症状筛查（以培养为参考标准）在艾滋病毒感染者总体及各亚组（住院患者、接受和未接受抗逆转录病毒治疗的门诊患者、CD4 ≤ 200个/µL者、孕妇）中检测结核病的敏感度和特异度（95%置信区间），并列出研究数和参与者人数，与世卫组织目标产品特征进行对照。",
        "es": "El cuadro presenta la sensibilidad y la especificidad (IC del 95%) de la detección de cuatro síntomas recomendada por la OMS, en comparación con el cultivo, para la TB en las personas con VIH en general y en subpoblaciones (pacientes hospitalizados, pacientes ambulatorios con y sin TAR, CD4 ≤ 200 células/µL, embarazadas), con el número de estudios y participantes, frente al perfil de producto objetivo de la OMS.",
        "fr": "Le tableau présente la sensibilité et la spécificité (IC à 95 %) du dépistage des quatre symptômes recommandé par l’OMS, par rapport à la culture, pour la tuberculose chez les personnes vivant avec le VIH, globalement et par sous-groupe (patients hospitalisés, patients ambulatoires sous TAR ou non, CD4 ≤ 200 cellules/µL, femmes enceintes), avec le nombre d’études et de participants, par rapport au profil de produit cible de l’OMS.",
        "ru": "В таблице приведены чувствительность и специфичность (95% ДИ) рекомендованного ВОЗ скрининга по четырём симптомам по сравнению с посевом для выявления ТБ у людей, живущих с ВИЧ, в целом и в подгруппах (стационарные пациенты, амбулаторные пациенты, получающие и не получающие АРТ, CD4 ≤ 200 клеток/мкл, беременные женщины), с числом исследований и участников, в сравнении с целевым профилем продукта ВОЗ."
      },
      "csv": "tables/table-5.csv"
    },
    {
      "label": "Table 6",
      "caption": "Table 6. Diagnostic accuracy of C-reactive protein using a cut-off > 5 mg/L among different subpopulations of people living with HIV compared with culture as a reference standard",
      "pages": [
        43
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "No. of studies (no. of participants)"
        },
        {
          "titles": "Sensitivity (95% CI)"
        },
        {
          "titles": "Specificity (95% CI)"
        }
      ],
      "rows": [
        [
          "WHO target product profile",
          "NA",
          "> 0.90",
          "> 0.70"
        ],
        [
          "All people living with HIV",
          "6 (3 971)",
          "0.90 (0.78–0.96)",
          "0.50 (0.29–0.71)"
        ],
        [
          "Inpatients",
          "1 (400)",
          "0.98 (0.93–1.00)",
          "0.12 (0.09–0.17)"
        ],
        [
          "Outpatients on ART",
          "1 (381)",
          "0.40 (0.10–0.80)",
          "0.80 (0.75–0.84)"
        ],
        [
          "Outpatients not on ART",
          "4 (3 186)",
          "0.89 (0.85–0.92)",
          "0.54 (0.45–0.62)"
        ],
        [
          "CD4 ≤ 200 cells/µL",
          "6 (1 829)",
          "0.93 (0.87–0.97)",
          "0.40 (0.22–0.62)"
        ],
        [
          "Pregnant women living with HIV",
          "2 (62)",
          "0.70 (0.12–0.97)",
          "0.41 (0.12–0.78)"
        ]
      ],
      "notes": "ART: antiretroviral treatment; CI: confidence interval; NA: not applicable.",
      "narratives": {
        "en": "The table gives the sensitivity and specificity (95% CI) of C-reactive protein at a cut-off of > 5 mg/L, compared with culture, for TB among people living with HIV overall and in subpopulations (inpatients, outpatients on and not on ART, CD4 ≤ 200 cells/µL, pregnant women), with the number of studies and participants, against the WHO target product profile.",
        "ar": "يعرض الجدول الحساسية والنوعية (مع فترات ثقة 95%) لـالبروتين التفاعلي C بعتبة > 5 ملغ/لتر، مقارنةً بالزرع، في الكشف عن السل لدى المتعايشين مع فيروس العوز المناعي البشري عمومًا وفي فئات فرعية (المرضى الداخليون، والمرضى الخارجيون الذين يتلقون أو لا يتلقون العلاج المضاد للفيروسات القهقرية، ومن لديهم CD4 ≤ 200 خلية/ميكرولتر، والحوامل)، مع عدد الدراسات والمشاركين، مقارنةً بالمواصفات المستهدفة للمنتج لدى المنظمة.",
        "zh": "本表列出了C反应蛋白（临界值> 5 mg/L，以培养为参考标准）在艾滋病毒感染者总体及各亚组（住院患者、接受和未接受抗逆转录病毒治疗的门诊患者、CD4 ≤ 200个/µL者、孕妇）中检测结核病的敏感度和特异度（95%置信区间），并列出研究数和参与者人数，与世卫组织目标产品特征进行对照。",
        "es": "El cuadro presenta la sensibilidad y la especificidad (IC del 95%) de la proteína C reactiva con un umbral > 5 mg/L, en comparación con el cultivo, para la TB en las personas con VIH en general y en subpoblaciones (pacientes hospitalizados, pacientes ambulatorios con y sin TAR, CD4 ≤ 200 células/µL, embarazadas), con el número de estudios y participantes, frente al perfil de producto objetivo de la OMS.",
        "fr": "Le tableau présente la sensibilité et la spécificité (IC à 95 %) de la protéine C-réactive au seuil > 5 mg/L, par rapport à la culture, pour la tuberculose chez les personnes vivant avec le VIH, globalement et par sous-groupe (patients hospitalisés, patients ambulatoires sous TAR ou non, CD4 ≤ 200 cellules/µL, femmes enceintes), avec le nombre d’études et de participants, par rapport au profil de produit cible de l’OMS.",
        "ru": "В таблице приведены чувствительность и специфичность (95% ДИ) C-реактивного белка при пороговом значении > 5 мг/л по сравнению с посевом для выявления ТБ у людей, живущих с ВИЧ, в целом и в подгруппах (стационарные пациенты, амбулаторные пациенты, получающие и не получающие АРТ, CD4 ≤ 200 клеток/мкл, беременные женщины), с числом исследований и участников, в сравнении с целевым профилем продукта ВОЗ."
      },
      "csv": "tables/table-6.csv"
    },
    {
      "label": "Table 7",
      "caption": "Table 7. Diagnostic accuracy among different subpopulations of people living with HIV of the WHO-recommended four-symptom screen combined with chest X-ray (any abnormality) compared with culture as the reference standard and using a positive or abnormal result on either screen or both",
      "pages": [
        44
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "No. of studies (no. of participants)"
        },
        {
          "titles": "Sensitivity (95% CI)"
        },
        {
          "titles": "Specificity (95% CI)"
        }
      ],
      "rows": [
        [
          "WHO target product profile",
          "NA",
          "> 0.90",
          "> 0.70"
        ],
        [
          "All people living with HIV",
          "8 (6 238)",
          "0.93 (0.88–0.96)",
          "0.20 (0.10–0.38)"
        ],
        [
          "Inpatients",
          "1 (52)",
          "0.90 (0.33–0.99)",
          "0.07 (0.03–0.19)"
        ],
        [
          "Outpatients on ART",
          "4 (2 670)",
          "0.85 (0.69–0.94)",
          "0.33 (0.15–0.58)"
        ],
        [
          "Outpatients not on ART",
          "8 (3 516)",
          "0.94 (0.89–0.96)",
          "0.19 (0.09–0.34)"
        ],
        [
          "CD4 ≤ 200 cells/µL",
          "8 (2 232)",
          "0.94 (0.90–0.97)",
          "0.14 (0.07–0.25)"
        ],
        [
          "Pregnant women living with HIV",
          "1 (8)",
          "0.75 (0.11–0.99)",
          "0.56 (0.24–0.84)"
        ]
      ],
      "notes": "ART: antiretroviral treatment; CI: confidence interval; NA: not applicable.",
      "narratives": {
        "en": "The table gives the sensitivity and specificity (95% CI) of the WHO-recommended four-symptom screen combined in parallel with chest X-ray (any abnormality), compared with culture, for TB among people living with HIV overall and in subpopulations (inpatients, outpatients on and not on ART, CD4 ≤ 200 cells/µL, pregnant women), with the number of studies and participants, against the WHO target product profile.",
        "ar": "يعرض الجدول الحساسية والنوعية (مع فترات ثقة 95%) لـفحص الأعراض الأربعة الذي توصي به المنظمة مقترنًا بالتصوير الشعاعي للصدر (أي شذوذ)، مقارنةً بالزرع، في الكشف عن السل لدى المتعايشين مع فيروس العوز المناعي البشري عمومًا وفي فئات فرعية (المرضى الداخليون، والمرضى الخارجيون الذين يتلقون أو لا يتلقون العلاج المضاد للفيروسات القهقرية، ومن لديهم CD4 ≤ 200 خلية/ميكرولتر، والحوامل)، مع عدد الدراسات والمشاركين، مقارنةً بالمواصفات المستهدفة للمنتج لدى المنظمة.",
        "zh": "本表列出了世卫组织推荐的四症状筛查与胸部X线（任何异常）并联组合（以培养为参考标准）在艾滋病毒感染者总体及各亚组（住院患者、接受和未接受抗逆转录病毒治疗的门诊患者、CD4 ≤ 200个/µL者、孕妇）中检测结核病的敏感度和特异度（95%置信区间），并列出研究数和参与者人数，与世卫组织目标产品特征进行对照。",
        "es": "El cuadro presenta la sensibilidad y la especificidad (IC del 95%) de la detección de cuatro síntomas de la OMS combinada en paralelo con la radiografía de tórax (cualquier anomalía), en comparación con el cultivo, para la TB en las personas con VIH en general y en subpoblaciones (pacientes hospitalizados, pacientes ambulatorios con y sin TAR, CD4 ≤ 200 células/µL, embarazadas), con el número de estudios y participantes, frente al perfil de producto objetivo de la OMS.",
        "fr": "Le tableau présente la sensibilité et la spécificité (IC à 95 %) du dépistage des quatre symptômes de l’OMS associé en parallèle à la radiographie thoracique (toute anomalie), par rapport à la culture, pour la tuberculose chez les personnes vivant avec le VIH, globalement et par sous-groupe (patients hospitalisés, patients ambulatoires sous TAR ou non, CD4 ≤ 200 cellules/µL, femmes enceintes), avec le nombre d’études et de participants, par rapport au profil de produit cible de l’OMS.",
        "ru": "В таблице приведены чувствительность и специфичность (95% ДИ) рекомендованного ВОЗ скрининга по четырём симптомам в сочетании с рентгенографией грудной клетки (любые изменения) по сравнению с посевом для выявления ТБ у людей, живущих с ВИЧ, в целом и в подгруппах (стационарные пациенты, амбулаторные пациенты, получающие и не получающие АРТ, CD4 ≤ 200 клеток/мкл, беременные женщины), с числом исследований и участников, в сравнении с целевым профилем продукта ВОЗ."
      },
      "csv": "tables/table-7.csv"
    },
    {
      "label": "Table 8",
      "caption": "Table 8. Diagnostic accuracy of molecular WHO-recommended rapid diagnostic tests for screening for TB among different subpopulations of people living with HIV compared with culture as a reference standard",
      "pages": [
        45
      ],
      "columns": [
        {
          "titles": "Population"
        },
        {
          "titles": "No. of studies (no. of participants)"
        },
        {
          "titles": "Sensitivity (95% CI)"
        },
        {
          "titles": "Specificity (95% CI)"
        }
      ],
      "rows": [
        [
          "WHO target product profile",
          "NA",
          "> 0.90",
          "> 0.70"
        ],
        [
          "All people living with HIV",
          "14 (9 209)",
          "0.69 (0.60–0.76)",
          "0.98 (0.97–0.99)"
        ],
        [
          "Inpatients",
          "4 (639)",
          "0.77 (0.69–0.84)",
          "0.93 (0.89–0.96)"
        ],
        [
          "Outpatients on ART",
          "4 (2 645)",
          "0.54 (0.20–0.84)",
          "0.99 (0.97–1.00)"
        ],
        [
          "Outpatients not on ART",
          "10 (5 796)",
          "0.72 (0.64–0.79)",
          "0.98 (0.98–0.99)"
        ],
        [
          "CD4 ≤ 200 cells/µL",
          "12 (3 422)",
          "0.76 (0.68–0.82)",
          "0.97 (0.95–0.98)"
        ],
        [
          "Pregnant women living with HIV",
          "4/473",
          "0.55 (0.33–0.75)",
          "0.99 (0.97–0.99)"
        ]
      ],
      "notes": "ART: antiretroviral treatment; CI: confidence interval; NA: not applicable.",
      "narratives": {
        "en": "The table gives the sensitivity and specificity (95% CI) of molecular WHO-recommended rapid diagnostic tests used for screening, compared with culture, for TB among people living with HIV overall and in subpopulations (inpatients, outpatients on and not on ART, CD4 ≤ 200 cells/µL, pregnant women), with the number of studies and participants, against the WHO target product profile.",
        "ar": "يعرض الجدول الحساسية والنوعية (مع فترات ثقة 95%) لـالاختبارات الجزيئية التشخيصية السريعة التي توصي بها المنظمة المستخدمة للتحري، مقارنةً بالزرع، في الكشف عن السل لدى المتعايشين مع فيروس العوز المناعي البشري عمومًا وفي فئات فرعية (المرضى الداخليون، والمرضى الخارجيون الذين يتلقون أو لا يتلقون العلاج المضاد للفيروسات القهقرية، ومن لديهم CD4 ≤ 200 خلية/ميكرولتر، والحوامل)، مع عدد الدراسات والمشاركين، مقارنةً بالمواصفات المستهدفة للمنتج لدى المنظمة.",
        "zh": "本表列出了用于筛查的世卫组织推荐分子快速诊断检测（以培养为参考标准）在艾滋病毒感染者总体及各亚组（住院患者、接受和未接受抗逆转录病毒治疗的门诊患者、CD4 ≤ 200个/µL者、孕妇）中检测结核病的敏感度和特异度（95%置信区间），并列出研究数和参与者人数，与世卫组织目标产品特征进行对照。",
        "es": "El cuadro presenta la sensibilidad y la especificidad (IC del 95%) de las pruebas diagnósticas rápidas moleculares recomendadas por la OMS utilizadas para el cribado, en comparación con el cultivo, para la TB en las personas con VIH en general y en subpoblaciones (pacientes hospitalizados, pacientes ambulatorios con y sin TAR, CD4 ≤ 200 células/µL, embarazadas), con el número de estudios y participantes, frente al perfil de producto objetivo de la OMS.",
        "fr": "Le tableau présente la sensibilité et la spécificité (IC à 95 %) des tests moléculaires de diagnostic rapide recommandés par l’OMS utilisés pour le dépistage, par rapport à la culture, pour la tuberculose chez les personnes vivant avec le VIH, globalement et par sous-groupe (patients hospitalisés, patients ambulatoires sous TAR ou non, CD4 ≤ 200 cellules/µL, femmes enceintes), avec le nombre d’études et de participants, par rapport au profil de produit cible de l’OMS.",
        "ru": "В таблице приведены чувствительность и специфичность (95% ДИ) рекомендованных ВОЗ молекулярных экспресс-тестов, применяемых для скрининга, по сравнению с посевом для выявления ТБ у людей, живущих с ВИЧ, в целом и в подгруппах (стационарные пациенты, амбулаторные пациенты, получающие и не получающие АРТ, CD4 ≤ 200 клеток/мкл, беременные женщины), с числом исследований и участников, в сравнении с целевым профилем продукта ВОЗ."
      },
      "csv": "tables/table-8.csv"
    }
  ],
  "coverage": [
    {
      "kind": "contents",
      "state": "found",
      "count": 37,
      "note": "outline"
    },
    {
      "kind": "sections",
      "state": "found",
      "count": 38,
      "note": "3 levels"
    },
    {
      "kind": "figures",
      "state": "found",
      "count": 2
    },
    {
      "kind": "tables",
      "state": "found",
      "count": 8
    },
    {
      "kind": "references",
      "state": "not-extracted",
      "note": "a references section is in the text (p57); its entries are not extracted"
    },
    {
      "kind": "glossary",
      "state": "not-extracted",
      "note": "a glossary section is in the text (p10); its entries are not extracted"
    },
    {
      "kind": "footnotes",
      "state": "not-extracted"
    },
    {
      "kind": "summaries",
      "state": "partial",
      "count": 37,
      "note": "37 of 38 sections"
    }
  ],
  "links": {
    "repo": "litlfred/who-iris",
    "branch": "main",
    "dir": "library/10665-340255"
  }
}
